Sage Journals: Discover world-class research

Abstract

Hypertrophic scarring is an aberrant wound-healing response to reestablish dermal integrity after an injury and can cause significant abnormalities in physical, aesthetic, functional, and psychological symptoms, impacting the patient's quality of life. There is currently no gold standard for preventing and treating hypertrophic scars. Therefore, many researchers have attempted to search for antihypertrophic scar agents with greater efficacy and fewer side effects. Natural therapeutics are becoming attractive as potential alternative anti-scarring agents because of their high efficacy, safety, biocompatibility, low cost, and easy accessibility. This review demonstrates various kinds of natural product-based therapeutics, including onion, vitamin E, Gotu kola, green tea, resveratrol, emodin, curcumin, and others, in terms of their mechanisms of action, evidence of efficacy and safety, advantages, and disadvantages when used as anti-scarring agents. We reviewed the literature based on data from in vitro, in vivo, and clinical trials. A total of 23 clinical trials were identified in this review; most clinical trials were ranked as having uncertain results (level of evidence 2b; n = 16). Although these natural products showed beneficial effects in both in vitro and in vivo studies of potential anti-scarring agents, there was limited clinical evidence to support their efficacy due to the limited quality of the studies, with individual flaws including small sample sizes, poor randomization, and blinding, and short follow-up durations. More robust and well-designed clinical trials with large-scale and prolonged follow-up durations are required to clarify the benefits and risks of these agents.

Keywords

hypertrophic scar scar natural products mechanisms of action evidence-based herbal medicine

Introduction

Hypertrophic scarring is an aberrant wound-healing response to reestablish dermal integrity after injury. Hypertrophic scars present as erythematous, indurated, and raised dermal scars that remain within the original injury margins.^1,2 They are characterized by the expressive amounts of fibroblast-derived extracellular matrix (ECM) at the site of a skin injury, resulting from an imbalance between ECM protein deposition and breakdown during wound repair.^2-4 When a hypertrophic scar develops, it can cause significant abnormalities in physical, aesthetic, functional, and psychological symptoms, impacting the patient's quality of life.^1,2,4

Currently, there are numerous therapeutic strategies to reduce and prevent the development of hypertrophic scars, such as silicone gel, pressure therapy, intralesional corticosteroid injections, and surgical revision. However, most of these therapeutic approaches remain clinically unsatisfactory for both patients and their providers. They are associated with high recurrent rates, high costs, and adverse effects such as pain, skin atrophy, contact dermatitis, and further scar formation. So far, there is no gold standard in preventing scarring.⁵ For this reason, the research and development of antihypertrophic scar agents with greater efficacy and fewer side effects remain an area of significant research interest at present.

In the last decade, the traditional use of natural products for healthcare, including wound and scar care, has renewed global interest due to the high cost and difficult accessibility of orthodox medicines.⁶ Almost 80% of people in developing countries have used herbal medicine to treat wounds and prevent scars.⁷ Currently, there is a large amount of research demonstrating the therapeutic potential of natural products for wound healing and scar management.^8-11 Several reviews summarize the wound-healing effect of natural products.^6,7 It is widely accepted that wound healing time is essential in predicting scar development.³ However, few reviews have focused on the scar management properties of natural products in the stage after wound healing.¹² Furthermore, levels of evidence have not yet been assigned to these reviews on the summarized data. The present study aims to gather the available clinical evidence supporting natural products as potential therapeutic agents for scar development, particularly hypertrophic scars, focusing on the management after wound healing. The potential mechanisms, side effects, and current administration of natural therapeutics are also described in this review. As knowledge of the wound healing process is crucial to understand better the effects of natural product-based therapeutics on hypertrophic scars, the pathomechanism of wound healing and hypertrophic scarring are also reviewed. This review will benefit future research on natural products for potential use as antihypertrophic scar agents.

Methods

To conduct the present narrative review, the literature from PubMed, Science Direct, and Google Scholar was searched, focusing on the effects of natural product-based therapeutics on hypertrophic scars in vitro, in vivo, and clinical trials (only randomized controlled trials; RCTs). The search keywords included “scar”, “hypertrophic scar”, “natural products”, and “medicinal plants”. The individual therapies’ names identified during the search were included, and the identified articles’ reference lists were further searched for relevant literature. All available English articles were reviewed. Studies in cell culture and animal models were considered in association with mechanisms of action. The level of evidence was assigned to each clinical trial using the Oxford Centre for Evidence-based Medicine.^13,14

Based on the findings from existing data, we have demonstrated and discussed the following issues: 1) pathomechanism of wound healing and scarring, particularly hypertrophic scarring, and 2) the effects of natural product-based therapeutics on hypertrophic scars, including phytochemicals, mechanisms of action, therapeutic efficacy, safety profile (if any), and examples of commercially available natural-based products.

Results

Pathomechanism of Wound Healing and Scarring, Particularly Hypertrophic Scarring

The wound healing process is comprised of three overlapping phases: inflammation (days 1-3), proliferation (days 4-21), and remodeling (days 21 to year 1). These three phases involve complicated interactions between cells (platelets, inflammatory cells, fibroblasts, endothelial cells, myofibroblasts, and keratinocytes), growth factors (transforming growth factor-beta (TGF-β), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and connective tissue growth factor (CTGF)), cytokines, ECM components (collagen, hyaluronan, and fibronectin), and proteolytic enzymes (matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs)). Hypertrophic scars can occur due to an aberration in these processes.⁴

The crucial wound-healing process for scar formation begins during the proliferation phase, where the granulation matrix provides a structural framework for wound bridging and vascular ingrowth by angiogenesis. Approximately one week after injury, some fibroblasts differentiate into myofibroblasts, activated by TGF-βI, which synthesize and deposit ECM components. Myofibroblasts, which contain alpha-smooth muscle actin (α-SMA), play a significant role in wound contraction, reducing the wound size. Simultaneously, re-epithelialization occurs by keratinocyte migration and proliferation across the injury site to close the wound surface. When re-epithelialization is complete, the immature scar can progress into the last remodeling phase, where the granulation tissue formation stops via apoptosis of the responsible cells. During this phase, collagen is remodeled and rearranged. The immature collagen type III found in the initial wound is broken down and replaced with mature collagen type I. The equilibrium between collagen deposition and breakdown is vital, regulated by matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). When this process is disrupted, it results in hypertrophic scarring (Figure 1).^2,4,15

Figure 1.

The mechanisms of wound healing and scarring.

Hypertrophic scar formation results from an imbalance between ECM protein deposition and breakdown during wound repair. The underlying mechanism is likely due to the aberrant and over-release of growth factors and cytokines and a lack of molecules responsible for cell apoptosis or ECM remodeling. The excessive inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), IL-6, and IL-8, promote fibroblast proliferation and ECM production, suppress collagenase activity, and enhance collagenase inhibitors activity, leading to abnormal collagen deposition and eventually to scar formation.¹⁵ TGF-β is the most representative cytokine in regulating wound scarring via the TGF-β/Smad signaling pathway. All three TGF-β isoforms (TGF-β1, -β2, and -β3) are released by numerous cells involved in wound healing, mainly macrophages, neutrophils, and platelets. Exaggerated TGF-β1 and -β2 levels stimulate collagen synthesis and prevent its breakdown by reducing MMP activity while promoting TIMP expression, resulting in scar formation. Conversely, TGF-β3 has an antagonist effect and thereby reduces scarring.^2,4

There are numerous hypertrophic scar-inducing signaling transduction pathways that play a role in the induction of cell proliferation, migration, and differentiation and the inhibition of cell apoptosis (Figure 2). Among them, the TGF-β/Smad signaling pathway is essential in hypertrophic scar development as it promotes ECM synthesis on fibroblast stimulation and induces fibroblast differentiation into myofibroblasts.^2,4,15,16 Other vital signaling pathways are the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) and mitogen-activated protein kinase (MAPK) pathways. MAPKs, consisting of the extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) pathways, participate in hypertrophic scars formation and promotion through their involvement in TGF-β signaling.¹⁶ Nonetheless, the complex mechanism of hypertrophic scarring is still not well understood.

Figure 2.

TGF-β/Smad signaling pathway and other related signaling pathways (Akt, protein kinase B; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; TGF-β, transforming growth factor-beta).

Effects of Natural Product-Based Therapeutics on Hypertrophic Scars

Some natural products have shown beneficial effects in the management of scars, particularly hypertrophic scars. In this study, natural product-based therapeutics, including onion (Allium cepa L.), vitamin E, Gotu kola (Centella asiatica (L.) Urb.), green tea (Camellia sinensis (L.) Kuntze), resveratrol, emodin, curcumin, and others, are reviewed. The preclinical evidence of the proposed mechanisms of action and the clinical evidence of these natural product-based therapeutics are summarized in detail (Tables 1, 2, and 3, respectively). The pros and cons of these natural product-based therapeutics are also shown in Table 4. Examples of commercially available natural-based products for scars are also provided in this review (Table 5).

Table 1.

Proposed Anti-Scarring Mechanisms of Natural Product-Based Therapeutics in This Review.

Natural sources	Natural products	Administered	Proposed mechanisms
Onion	Quercetin	In vitro (human NFs and HSFs with 5–20 μg/ml quercetin)¹⁷ In vitro (rat mast cells with 0.5 mg/ml quercetin)¹⁸ In vivo (anaphylactic sensitized rats with 25 mg/kg quercetin, oral administration)¹⁸ In vitro (human NFs with 1–2.5% (v/v) onion extract and 10–40 μM quercetin)²² In vivo (hairless mice with 0.05–0.1% quercetin ointment, topical application)²² In vitro (human KFs with 5–20 μg/ml quercetin)²³ In vitro (human KFs with 10–50 μg/ml quercetin)²⁴	Inhibition or retardation of collagen contraction¹⁷ Anti-inflammatory effect and downregulation of collagen overproduction by fibroblasts through mast cell stabilization, leading to reduction of histamine release^18-20 Anti-scarring effect through activation of JNK and ERK followed by upregulation of MMP-1 expression²² Inhibition of KF proliferation and collagen production through suppression of transcriptional coactivators p300 and CBP levels, blocking of TGF-β/Smad signaling pathway,²³ and inhibition of IGF-I signaling pathways such as Akt-1, MAPK, c-Raf, PI3K, and Elk-1²⁴
Number of foods, such as green leafy vegetables, vegetable oils, nuts, and seeds	Vitamin E	In vitro (human Tenon's capsule fibroblasts with 10–100 μM vitamin E)³⁹ In vitro (rabbit corneal keratocytes with 10⁻⁴, 10⁻⁷, and 10⁻⁹ M vitamin E)⁴⁰ In vivo (hairless rats for incisional wound healing model with 190 IU vitamin E, intramuscular injection)⁴¹ In vitro (human NFs with 20 μg/ml vitamin E)⁴² In vivo (normal and diabetic rats for incisional wound healing model with 200 mg/kg vitamin E, oral administration)⁴³	Anti-scarring effect through inhibition of fibroblast proliferation^39,41 and collagen synthesis^40,41 Scar remodeling effect by functioning as an antioxidant that inhibits and prevents lipid peroxidation in cellular membranes by reducing ROS and increasing GPx, leading to induction of molecular packing and maintenance of biological membrane stability^41-44
		In vivo (hairless mice for ultraviolet light-induced skin damage model with 2, 60, and 600 IU/kg vitamin E, oral administration; 1% vitamin E, topical application)⁴⁴
Gotu kola	Madecassoside	In vitro (human KFs with 10–100 μM madecassoside)⁵⁹ In vitro (human KFs with 10–100 μM madecassoside)⁶⁰	Inhibition of KF proliferation⁵⁹ Promotion of KF apoptosis through a mitochondrial-dependent pathway by upregulation of Bax (pro-apoptotic protein) expression, downregulation of Bcl-2 (anti-apoptotic protein) expression, activation of mitochondrial membrane depolarization, and induction of caspase-3 and -9⁵⁹ Inhibition of KF migration through attenuating P-cofilin, p38 MAPK, and PI3K/Akt signaling⁶⁰
	Asiaticoside	In vitro (human KFs with 100–500 mg/L asiaticoside)⁶¹ In vivo (rabbit ear hypertrophic scar model with 0.5–1.0% asiaticoside solution, topical application)⁶²	Inhibition of KF proliferation and collagen type I and type III production through inhibiting TGF-βRI and TGF-βRII expressions⁶¹ and inducing Smad7 expression^61,62 Anti-scarring effect through decreasing TGF-βI expression⁶²
	Asiatic acid	In vitro (human KFs with 3–30 μM asiatic acid)⁶³	Anti-scarring effect on TGF-β/Smad signaling via PPAR-γ induction in KFs by inhibiting TGF-βI-induced type I collagen expression, Smad2/3 phosphorylation, and PAI-1 expression, while increasing Smad7 protein level⁶³
Green tea	EGCG	In vitro (human KFs co-cultured with human mast cells with 25–100 μM EGCG)⁷⁷	Inhibition of mast cell-stimulated collagen type I production through inhibiting PI3K/Akt signaling pathway^77,78
		Ex vivo (human keloid organ culture with 100 μg/ml EGCG)⁷⁸ In vitro (human KFs with 25–100 μM EGCG)⁷⁹ In vivo (nude mice implanted with human KFs and treatment with 1.5 mg EGCG, intralesional injection)⁷⁹ In vitro (human NFs with 6.25–25 μM EGCG)⁸⁰ In vitro (human and rat vascular smooth muscle cells with 50 μM EGCG)⁸¹ In vitro (human NFs with 50 μM EGCG)⁸² In vitro (rat hepatic stellate cells with 10–80 μM EGCG)⁸³	Inhibition of KF proliferation and migration and collagen production through suppressing STAT3 signaling pathway^78,79 Inhibition of cell proliferation and collagen contraction by interacting directly between EGCG and PDGF-BB, thereby preventing specific receptor binding^80,81 Inhibition of TGF-βI on collagen production and contraction through downregulation of CTGF gene expression and decrease in fibroblast to myofibroblast differentiation⁸² Anti-fibrogenic effect by disrupting TGF-β signaling through inhibiting TGF-βRI and TGF-βRII gene expressions, thereby reducing TGF-βI bioavailability and also inhibiting CTGF gene expression, resulting in a reduction of ECM abundance⁸³
	ECG	In vivo (normal rats for incisional wound healing model with 0.8 mg/ml ECG, intradermal injection)⁸⁵ In vivo (diabetic rats for incisional wound healing model with 0.8 mg/ml ECG, intradermal injection)⁸⁶	Improvement in wound healing and scar quality in terms of collagen orientation and maturity through an acceleration of angiogenic response and upregulation of iNOS and COX-2^85,86
Grapes, red wine, peanuts, and soy	Resveratrol	In vitro (human HSFs and NFs with 25–400 μM resveratrol)⁹⁸ In vitro (human PSFs with 10–100 μmol/l resveratrol)¹⁰⁰ In vitro (human KFs and NFs with 25–100 μM resveratrol)¹⁰¹	Reduction of collagen protein by suppressing cell growth, arresting G₁-phase cell cycle, inducing apoptosis, and downregulating procollagen type I and III mRNA expression in fibroblasts⁹⁸
		In vitro (human HSFs and NFs with 1–100 μM resveratrol)¹⁰² In vitro (human PSFs and NFs with 10–100 μM resveratrol)¹⁰³ In vitro (human HSFs and NFs with 2.5–40 μM resveratrol)¹⁰⁴ In vivo (mice for cutaneous excision wound model with 4.4 mM, 0.5 ml/100 g bodyweight of resveratrol, intradermal injection)¹⁰⁴	Inhibition of PSF proliferation and activation of cell apoptosis through altering TGF-βI/Smad signaling pathway by downregulating TGF-βI and Smad-2, 3, 4 and upregulating Smad7 mRNA/protein expression¹⁰⁰ Inhibition of KF proliferation and type I collagen accumulation and induction of cell apoptosis, through suppression of TGF-βI production¹⁰¹ Anti-scarring effect by activating autophagy through upregulating microRNA-4654 expression and thus downregulating Rheb expression¹⁰² Inhibition of PSF proliferation through altering mTOR/70S6K signaling pathway by downregulation of mTOR and 70S6K mRNA and protein expression¹⁰³ Anti-scarring effect through upregulating SIRT1 and therefore decreasing collagen type I, collagen type III, and α-SMA expression and also blocking the TGF-βI-induced fibroblasts- to-myofibroblasts differentiation, resulting in the improvement of collagen fiber density and arrangement¹⁰⁴
Chinese medicinal herbs, such as rhubarb, Japanese knotweed, and Chinese climbing knotweed	Emodin	In vitro (mice HSFs and NFs with 20, 40, 80, and 120 mg/ml emodin)¹¹³ In vivo (mechanical stress-induced murine hypertrophic scar model with 10 mg/kg emodin, intraperitoneal injection)¹¹³ In vitro (rat-isolated macrophages with 50 μg/ml emodin)¹¹⁴	Inhibition of inflammation in mechanical stress-induced hypertrophic scar by suppressing the recruitment and adhesion of inflammatory cells and attenuating inflammatory cytokine production, which is related to the downregulation of the PI3K/Akt signaling pathway¹¹³
		In vivo (tail hypertrophic scar and dorsal subcutaneous PVA sponge implantation-induced wound in rat model with 10 mg/kg body weight of emodin, intraperitoneal injection)¹¹⁴	Inhibition of hypertrophic scar development and fibrosis by inhibiting macrophage polarization and recruitment and the Notch and TGF-β signaling pathways in macrophages¹¹⁴
Turmeric	Curcumin	In vitro (human KFs and HSFs with 1–5 μg/ml curcumin)¹⁷ In vitro (human NFs with 2.5–25 μM curcumin)¹²² In vitro (human KFs with 25–100 nM curcuminoids)¹²³ In vivo (rabbit ear hypertrophic scar model with 6 and 30 μg/kg body weight of curcumin, intravenous injection)¹²⁴	Inhibition of fibroblast proliferation by activating cell growth arrest and collagen contraction¹⁷ Induction of fibroblast apoptosis and inhibition of collagen gel contraction mediated by fibroblasts through a ROS-mediated mechanism¹²² Inhibition of TGF-βI/Smad signaling pathway and ECM synthesis in KFs¹²³ Reduction of hypertrophic scar formation by suppressing the release of IL-1, IL-6, and IL-8¹²⁴

Abbreviations: 70S6K, ribosomal protein S6 kinase; Akt, protein kinase B; CBP, CREB-binding protein; COX-2, cyclooxygenase-2; CREB, cAMP response element binding protein; CTGF, connective tissue growth factor; d, day; ECG, epicatechin-3-gallate; ECM, extracellular matrix; EGCG, epigallocatechin-3-gallate; ERK, extracellular signal-regulated kinase; GPx, glutathione peroxidase; HSFs, hypertrophic scar-derived fibroblasts; IGF-I, insulin-like growth factor-I; IL, interleukin; iNOS, inducible nitric oxide synthase; JNK, c-Jun N-terminal kinase; KF, keloid scar-derived fibroblast; MAPK, mitogen-activated protein kinase; MMP-1, matrix metalloproteinase-1; mRNA, messenger ribonucleic acid; mTOR, mammalian target of rapamycin; NFs, normal skin fibroblasts; PAI-1, plasminogen activator inhibitor-1; P-cofilin, phosphorylated cofilin; PDGF-BB, platelet-derived growth factor-BB; PI3K, phosphatidylinositol 3-kinase; PPAR-γ, peroxisome proliferator-activated receptors-gamma; PSF, pathological scar-derived fibroblast; PVA, polyvinyl alcohol; Rheb, Ras homolog enriched in brain; ROS, reactive oxygen species; SIRT1, sirtuin 1; STAT3, signal transducer and activator of transcription-3; TGF-β, transforming growth factor-beta; TGF-βR, transforming growth factor-beta receptor; α-SMA, alpha-smooth muscle actin.

Table 2.

Summary of Proposed Anti-Scarring Mechanisms of Natural Product-Based Therapeutics in This Review.

Anti-scarring mechanisms		Natural products
MAPK signaling pathways	ERK signaling	Quercetin (onion)
	JNK signaling	Quercetin (onion)
	p38 signaling	Madecassoside (Gotu kola)
PI3K/Akt signaling pathway		Madecassoside (Gotu kola), EGCG (green tea), Emodin
TGF-β/Smad signaling pathway	Downregulation of TGF-βI expression	Asiaticoside (Gotu kola), Resveratrol, Emodin, Curcumin
	Inhibition of TGF-βRI and TGF-βRII expressions	Quercetin (onion), Asiaticoside (Gotu kola), EGCG (green tea)
	Inhibition of Smad2/3 phosphorylation	Quercetin (onion), Asiatic acid (Gotu kola), Curcumin
	Downregulation of Smad-2, 3, 4 expressions	Quercetin (onion), Resveratrol, Emodin, Curcumin
	Induction of Smad7 expression	Asiaticoside (Gotu kola), Asiatic acid (Gotu kola), Resveratrol
IGF-I signaling pathway		Quercetin (onion)
mTOR/70S6K signaling pathway		Resveratrol
Suppression of transcriptional coactivators p300 and CBP levels		Quercetin (onion)
STAT3 signaling pathway		EGCG (green tea)
Mitochondrial-dependent pathway	Upregulation of Bax expression	Madecassoside (Gotu kola)
Mitochondrial-dependent pathway	Downregulation of Bcl-2 expression	Madecassoside (Gotu kola)
Activation of caspases	Activation of caspase-3	Madecassoside (Gotu kola)
Activation of caspases	Activation of caspase-9	Madecassoside (Gotu kola)
Cell cycle	Activation of G₁-phase cell cycle arrest	Resveratrol
Cell cycle	Induction of cell cycle arrest	Curcumin
Collagen	Downregulation of collagen type I expression	Asiatic acid (Gotu kola), Resveratrol
Collagen	Downregulation of collagen type III expression	Resveratrol
MMP	Upregulation of MMP-1 expression	Quercetin (onion)
Downregulation of α-SMA expression		Resveratrol
Downregulation of CTGF expression		EGCG (green tea)
Prevention of PDGF binding to specific receptors		EGCG (green tea)
Downregulation of inflammatory cytokines such as TNF-α, IL-1, IL-6, and IL-8,		Emodin, Curcumin
Reduction of ROS and Increase of GPx activity		Vitamin E
Increase of ROS		Curcumin
Upregulation of microRNA-4654 expression and downregulation of Rheb expression		Resveratrol

Abbreviations: 70S6K, ribosomal protein S6 kinase; Akt, protein kinase B; CBP, CREB-binding protein; CREB, cAMP response element binding protein; CTGF, connective tissue growth factor; EGCG, epigallocatechin-3-gallate; ERK, extracellular signal-regulated kinase; GPx, glutathione peroxidase; IGF-I, insulin-like growth factor-I; IL, interleukin; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; mTOR, mammalian target of rapamycin; PDGF, platelet-derived growth factor; PI3K, phosphatidylinositol 3-kinase; Rheb, Ras homolog enriched in brain; ROS, reactive oxygen species; STAT3, signal transducer and activator of transcription-3; TGF-β, transforming growth factor-beta; TGF-βR, transforming growth factor-beta receptor; TNF-α, tumor necrosis factor-alpha; α-SMA, alpha-smooth muscle actin.

Table 3.

Clinical Trials of Natural Product-Based Therapeutics Identified in This Review.

Author (year)	Study design	Type of wound	Number of subjects	Number of wounds	Patients with a previous HS or KS	Intervention	Treatment administration	Comparator	Follow-up duration	Evaluation Method	Outcomes and AEs (if any)	LoE
Prager et al (2018)²⁵	Intra-individual, single-blinded, RCT	Post-dermatologic surgery scars within 3 wk after surgical procedure	124	248	Excluded	Onion extract patch containing allantoin (Contractubex^® Overnight Intensive Patch; Merz Pharma, Frankfurt, Germany)	Applied before going to bed for 6–12 h/d for at least 12 wk	No treatment	12–24 wk	POSAS and GAIS (assessor and patients); global comfort assessment scale and scar appearance satisfaction (patients)	- Significant improvement in POSAS observer scale at 6 and 24 wk, POSAS patient scale at 12 and 24 wk, and GAIS at all visits for onion extract patch compared to the control - Reported global comfort of treated scar to be good or very good, and more satisfied with the appearance of a treated scar than untreated scar - Reported mild to moderate TEAEs including pruritus (n = 12), erythema (n = 11), skin irritation (n = 1), dermatitis (n = 1), contact dermatitis (n = 1), eczema (n = 1), blister (n = 1), swollen face (n = 1), and wound dehiscence (n = 1) in onion extract group - No reported serious AEs	2b
Song et al (2018)²⁶	Double-blinded, RCT	Gynecologic laparoscopic surgical wounds after suture removal	90	90	N/A	Silicone gel (Kelo-cort^®; Advanced Bio-Technologies, Silverdale, WA, USA) Onion extract gel (Contractubex^®; Merz Pharma, Frankfurt, Germany)	Twice daily for 12 wk	No treatment	12 wk	VSS and IPS (assessor); BIS and CS (patients)	- Significant improvement in all studied outcomes between the two gel groups compared to the control; however, no significant difference between the two gel groups - Two subjects of mild itching or irritation in both gel groups - No reported serious AEs	1b
Jenwitheesuk et al (2012)²⁷	Double-blinded, RCT	Median sternotomy wounds at 1 wk after surgical procedure	54	54	N/A	Silicone derivative plus onion extract gel (Cybele^® Scagel; Bangkok Botanica, Bangkok, Thailand)	Twice daily for 12 wk	Placebo gel	12 wk	VSS (assessor); pain and itching using a 10-point scale (patients)	- Significant improvement in pain and itching scores and pigmentation according to the VSS for the intervention group compared to placebo - No reported AEs	1b
Wananukul et al (2013)²⁸	Intra-individual, split-scar, double-blinded, RCT	Median sternotomy wounds at 1 wk after open-heart surgical procedure	30	60	N/A	Silicone derivative plus onion extract gel (Cybele^® Scagel; Bangkok Botanica, Bangkok, Thailand)	Twice daily for 6 mo	Placebo gel	6 mo	HS and KS incidence (assessor); VSS (assessor)	- Significantly lower HS incidence in the intervention group, while no significant difference in KS incidence and VSS scores between the two groups - One reported case of pustule in the intervention group	1b
Hosnuter et al (2007)²⁹	RCT	HS and KS with a duration from 1 mo to 6 mo	60	60	N/A	Onion extract gel (Contractubex^®; Merz Pharma, Frankfurt, Germany) Combination of onion extract and SGS	Onion extract gel applied four times daily for 6 mo SGS applied twice daily for 6 mo	SGS	6 mo	Scar color, height, hardness, itching, and pain using a 3- or 4-point scale (patients)	- Significant improvement in scar color for onion extract gel compared to SGS, while SGS was superior in decreasing scar height - No significant difference in scar hardness, itching, and pain among all groups - The best response was in combined onion extract with SGS - Mild itching in 20% of patients treated with onion extract	2b
Koc et al (2008)³⁰	Open, RCT	HS and KS with a duration from 0 mo to more than 2 yr	27	27	N/A	Combination of intralesional TAC and onion extract gel (Contractubex^®; Merz Pharma, Frankfurt, Germany)	Intralesional TAC 40 mg/ml every 4 wk for 4 treatments Onion extract gel applied thrice daily for 12 wk	Intralesional TAC	20 wk	Erythema, induration, pain sensitiveness, elevation, and itching using a 4-point scale (assessor and patients)	- Combining TAC and onion extract gel was superior to TAC alone in reducing pain sensitiveness, elevation, and itching but not in terms of erythema and induration - Three reported cases of itching in combined TAC with onion extract gel, whereas no reported AEs in TAC alone group - No reported serious AEs	2b
Hassanpour et al (2020)³¹	Double-blinded, RCT	Postsurgical upper extremity wounds after suture removal	107	107	Excluded	Silicone gel (Kelo-cort^®; Advanced Bio-Technologies, Silverdale, WA, USA) Onion extract gel (Contractubex^®; Merz Pharma, Frankfurt, Germany)	Silicone gel applied once daily for 4 mo Onion extract gel applied twice daily for 4 mo	No treatment	4 mo	VSS (assessor)	- No significant difference in vascularity, pliability, pigmentation, and height according to the VSS among the three groups - Lower overall VSS score in the untreated control compared to intervention groups	2b
Karagoz et al (2009)³²	RCT	Postburn HS with duration less than 6 mo	45	45	N/A	Onion extract gel (Contractubex^®; Merz Pharma, Frankfurt, Germany)	Onion extract gel applied twice daily for 6 mo Silicone gel applied twice daily for 6 mo SGS applied 24 h once daily for 6 mo	Silicone gel (Scarfade^®; Hanson Medical Inc. Kingston, WA, USA) SGS (Epi-Derm^®; Biodermis, Las Vegas, NV, USA)	6 mo	VSS (assessor)	- Significant improvement in VSS scores for both silicone groups compared to onion extract gel; however, no significant difference between the two silicone groups - Two subjects of pruritis and maceration in SGS; no reported AEs in the other two groups	2b

Chung et al (2006)³³	Intra-individual, split-scar, double-blinded, RCT	Post-Mohs or -excision surgical wounds after suture removal	24	48	N/A	Onion extract gel (Mederma^®; Merz Pharmaceuticals, Greensboro, NC, USA)	Thrice daily for 2 mo	Petrolatum ointment (Aquaphor^®; Beiersdorf, Inc., Wilton, CT, USA)	11 mo	Overall cosmetic appearance, erythema, and thickness using a 10-point VAS scale (assessor); erythema, pruritus, burning, and pain using a 10-point VAS scale (patients); overall cosmetic appearance using phone interview (patients)	- No significant difference between the two groups in any studied outcomes at all follow-up time points - No reported AEs	2b
Owji et al (2018)³⁴	Intra-individual, double-blinded, RCT	Upper eyelid blepharoplasty wounds after suture removal	43	86	N/A	Onion extract gel (Contractubex^®; Merz Pharma, Frankfurt, Germany)	Twice daily for 2 mo	Petroleum jelly	6 mo	MSS and overall scar appearance using a 10-point VAS scale (assessor); scar redness and appearance using phone interview (patients)	- No signiﬁcant difference between the two groups in any studied outcomes - Eleven reported cases of local reaction, including itching, burning, and redness, in the intervention group, whereas no reported local AEs in the control group	2b
Owji et al (2020)³⁵	Double-blinded, RCT	Upper eyelid blepharoplasty wounds after suture removal	37	74	N/A	Onion extract gel on the right eyelids of the first group's cases (Contractubex^®; Merz Pharma, Frankfurt, Germany) Topical corticosteroid on the right eyelids of the second group's cases (1% hydrocortisone eye ointment; Sina Darou, Karaj, Iran)	Twice daily for 2 mo	Petrolatum emollient on the left eyelids of both the first and second groups’ cases	2 mo	MSS (assessor); overall scar appearance using a 10-point VAS scale (assessor)	- No significant difference between onion extract gel and topical steroid groups, and among the three groups in any studied outcomes	1b
Baumann et al (1999)⁴⁷	Intra-individual, split-scar, double-blinded, RCT	Post-Mohs surgical wounds	15	30	N/A	Petrolatum ointment (Aquaphor^®; Beiersdorf, Inc., Wilton, CT, USA) with vitamin E (vitamin E 320 IU/g)	Twice daily for 4 wk	Petrolatum ointment (Aquaphor^®; Beiersdorf, Inc., Wilton, CT, USA)	12 wk	Subjective cosmetic appearance (assessor and patients)	- In most patients (90%), vitamin E was either no better or worse in cosmetic scar appearance compared to the control - Contact dermatitis in 33% of patients treated with vitamin E	2b
Khoo et al (2011)⁴⁸	Double-blinded, RCT	Clean or clean-contaminated surgical wounds at 2 wk after surgical procedure	85	85	N/A	5% topical tocotrienol cream	Twice daily for 6 wk	Placebo cream	16 wk	POSAS (assessor and patients); photographic scar assessment using a 10-point VAS scale and LDI (assessor)	- No significant difference between the two groups in any studied outcomes - Three reported cases of mild itching in tocotrienol cream - No reported serious AEs	2b
Zampieri et al (2010)⁴⁹	Single-blinded, RCT	Inguinal surgical wounds	428	428	Excluded	Topical vitamin E (Vea^® Lipogel; Hulka s.r.l, Rovigo, Italy)	Thrice daily before surgery for at least 15 d and twice daily after surgery for at least 30 d	Petrolatum-based ointment	6 mo	VSS (patients’ parents); cosmetic appearance satisfaction using a 4-point scale (assessor and patients’ parents)	- Significant improvement in cosmetic appearance for the intervention group compared to the control - No patients of keloid formation in the intervention group, while 13 (6.5%) patients of keloid formation in the control group - No reported AEs	2b
Palmieri et al (1995)⁵⁰	RCT	Postsurgical or postburn HS and KS with a duration from 3 mo to 2 yr	80	80	N/A	SGS with vitamin E (3% vitamin E per SGS)	Applied once daily, wearing overnight between 10 PM and 8 AM for 8 wk	SGS	8 wk	Itching and pain using a Scott-Husskinson scale (patients); color, size, and cosmetic appearance using a 5-point scale	- Significant improvement in overall studied outcomes for SGS with vitamin E compared to SGS	2b
Saeidinia et al (2017)⁶⁴	Double-blinded, RCT	Partial-thickness burn wounds	60	60	N/A	Gotu kola ethanolic extract ointment (Centiderm^®; Guilan University of Medical Sciences, Iran)	Once daily for 25 d	1% SSD cream	25 d	Burning wound VSS, VAS, dryness, itching, irritation, re-epithelialization time, and complete wound healing time (assessor)	- Significant improvement in all studied outcomes for the intervention group compared to the control - No reported AEs in the intervention group, while four reported cases of wound infection in the control group	2b
Damkerngsuntorn et al (2020)⁶⁵	Intra-individual, split-face, double-blinded, RCT	Bilateral atrophic facial acne scars after Er:YAG laser treatment	30	60	Excluded	0.05% (w/w) Gotu kola extract gel (51% madecassoside and 38% asiaticoside)	Four times daily for 7 d then twice daily for 3 mo	Placebo gel	3 mo	Erythema, melanin, texture index, and skin biophysics (skin moisture, TEWL, and skin pH) using objective assessment; erythema, crusting, epithelial confluence, and overall wound appearance using subjective assessment (assessor)	- Significant improvement in erythema by both objective and subjective assessments for the intervention group compared to placebo - Significant improvement in erythema, crusting, and overall wound appearance by subjective assessment within the first week for the intervention group compared to placebo - No significant difference in skin biophysics, dryness, itching, burning, and pain between the two groups - No reported other AEs	1b
Paocharoen (2010)⁶⁶	RCT	Diabetic foot ulcers	170	170	N/A	Gotu kola extract capsule (50 mg asiaticoside per capsule)	2 capsules after a meal thrice daily for 21 d	Placebo capsule	21 d	Wound contraction using the decrease of wound volume (assessor); wound granulation tissue forming using the decrease of wound depth (implies scar-forming and keloid formation) (assessor)	- Significantly better wound contraction and scar suppression in the intervention group compared to placebo - No reported systemic AEs or complications	2b
Jenwitheesuk et al (2018)⁶⁷	Intra-individual, split-scar, double-blinded, RCT	STSG donor sites after completed epithelialization	23	46	N/A	7% (w/w) Gotu kola alcoholic extract cream (5.12% asiaticoside and 5.1% madecassoside)	Twice daily for 12 wk	Placebo cream	12 wk	VSS (assessor)	- Significant improvement in pigmentation and overall VSS score between 4 and 12 wk in the intervention group - One reported case of allergic dermatitis in each group	2b
Chuangsuwanich et al (2014) ⁶⁸	Intra-individual, double-blinded, RCT	Postsurgical wounds with bilaterally symmetrical patterns after suture removal	17	34	N/A	Combined herbal extracts gel (12% (w/w) onion extract, 5% (w/w) Gotu kola extract, 4% (w/w) aloe extract, 1.5% (w/w) Indian gooseberry^a extract, and 1.5% (w/w) tamarind^b extract)	Twice daily for 12 wk	Placebo gel	12 wk	POSAS (assessor and patients)	- Significant improvement in total score, color, stiffness, thickness, and irregularity according to the POSAS patient scale and in total score, pigmentation, and thickness according to the POSAS observer scale at 12 wk for the intervention group compared to placebo - No reported AEs	2b
Surakunprapha et al (2020)⁶⁹	Double-blinded, RCT	Median sternotomy wounds at 2 wk after surgical procedure	46	46	Included	Combined silicone gel with 15% herbal extracts (onion extract, Gotu kola extract, aloe extract, and paper mulberry^c extract)	Applied for 6 mo	Placebo gel	6 mo	VSS (assessor)	- Significant improvement in height and pliability according to the VSS for the intervention group compared to placebo - No significant difference between the two groups in vascularity and pigmentation; however, better improvement in the intervention group - No reported AEs	1b
Ud-Din et al (2019)⁸⁸	Intra-individual, double-blinded, RCT	Biopsy wound on both upper inner arms	62	124	Excluded	Topical EGCG	Zonal priming: applied twice daily around the wound site after wounding immediately for 2 wk Direct application: applied twice daily directly onto the scar (2-wk-old scar) for 6 wk	Topical placebo	2–6 wk	Tissue morphology, blood flow, skin elasticity, skin hydration, TEWL, erythema, and melanin using noninvasive quantitative devices; immunohistochemical analysis, mRNA sequencing, and qRT-PCR of tissue biopsy samples	- Significant reduction in scar thickness, mast cells, and angiogenesis, and improvement in scar elasticity, hydration, and antioxidant effects for EGCG compared to placebo	1b
Ma et al (2018)¹⁰⁵	RCT	Scarred uterus	78	78	N/A	Resveratrol	Took 10 mg daily for 3 mo	Placebo	3 mo	Uterine-scar thickness and remodeling using ultrasound examination	- Significant improvement in uterine-scar thickness and scar remodeling for resveratrol compared to placebo	2b

Abbreviations: AEs, adverse events; BIS, Body Image Scale; CS, Cosmetic Scale; d, day; EGCG, epigallocatechin-3-gallate; Er:YAG, erbium-doped yttrium aluminum garnet; GAIS, Global Aesthetic Improvement Scale; h, hour; HS, hypertrophic scars; IPS, Image Panel Scale; KS, keloids; LDI, laser Doppler imaging; LoE, level of evidence; mo, month; mRNA, messenger ribonucleic acid; MSS, Manchester Scar Scale; N/A, not available; POSAS, Patient and Observer Scar Assessment Scale; qRT-PCR, quantitative real-time reverse transcriptase-polymerase chain reaction; RCT, randomized controlled trial; SGS, silicone gel sheet; SSD, silver sulfadiazine; STSG, split-thickness skin graft; TAC, triamcinolone acetonide; TEAEs, treatment-emergent adverse events; TEWL, transepidermal water loss; VAS, Visual Analogue Scale; VSS, Vancouver Scar Scale; wk, week; yr, year.

= Phyllanthus emblica L., ^b= Tamarindus indica L., ^c= Broussonetia papyrifera (L.) L'Hér. ex Vent.

Table 4.

Pros and Cons of Natural Product-Based Therapeutics in Scar Management.

Natural products	Pros	Cons
Onion	Widespread availability of topical scar treatment products Well tolerated May help in preventing hypertrophic scarring and improving cosmetic scar appearance, especially in combination with other therapies	Limited clinical trials on the combination therapy with onion extract
Vitamin E	May improve cosmetic scar appearance, especially in combination with other therapies	High incidence of contact dermatitis May cause widened scars and wound dehiscence when early use of vitamin E Limited clinical trials on the potential beneficial effect of vitamin E
Gotu kola	Well tolerated Increases tensile wound strength (in contrast to vitamin E) May improve cosmetic scar appearance, especially in scar hyperpigmentation	Limited clinical trials on the potential beneficial effect of Gotu kola
Green tea	Well tolerated	Limited clinical trials on the potential beneficial effect of EGCG Low bioavailability of EGCG Lack of EGCG stability at high temperatures and pH conditions may hinder its dermatological application.
Resveratrol	Widespread availability in different plant species and dietary sources	Limited clinical trials on the potential beneficial effect of resveratrol Fast metabolization and excretion
Emodin	Widespread availability in Chinese medicinal herbs and herb preparations	Limited clinical trials on the potential beneficial effect of emodin Low intestinal absorption, rapid elimination, and poor oral bioavailability Reproductive toxicity, hepatotoxicity, and nephrotoxicity, especially in high doses and prolonged use
Curcumin	Well tolerated and safe without serious adverse events Widespread availability Low cost	Limited clinical trials on the potential beneficial effect of curcumin Poor water solubility, low absorption, fast metabolism, fast elimination, poor bioavailability, photosensitivity, and yellow staining on the skin and clothes

Abbreviations: EGCG, epigallocatechin-3-gallate.

Table 5.

Examples of Commercially Available Natural-Based Products for Scars.

Natural products	Examples of commercial products
Onion	Contractubex^®, Mederma^®, Cybele^® Scagel (combined with Gotu kola extract, aloe extract, tamarind^a extract, Indian gooseberry^b extract, paper mulberry^c extract, silicone derivative, and vitamin E), Eraśe^® Gel (combined with vitamin E), Kaloidon gel, Derma E Scar Gel, Uderma Bio Scar Care Gel (combined with Gotu kola extract)
Vitamin E	Vea^® Lipogel, Scarguard ScarCare^® (combined with hydrocortisone and silicone), Scarguard^® Vitamin E Sheets (combined with silicone gel sheet), Curad^® Scar Therapy, Palmer's^® Cocoa Butter Formula^® Vitamin E Scar Serum (combined with cocoa^d butter, safflower^e oil, onion extract, and silicone), Dr Blaine's Complete ScarCare Treatment^® (combined with silicone gel sheet), ScarSof^® Scar Softening Cream (combined with aloe extract, vitamin E, and vitamin A)
Gotu kola	Alpha Centella^® (combined with stalked bulbine^f extract), Madecassol^®, Centellase^®, Blastoestimulina^® (combined with neomycin sulfate), Cytol Centella^®, Centiderm^®, Cothyline^®, Uderma Bio Scar Care Gel (combined with onion extract)
Green tea	100% PURE^® Green Tea EGCG Concentrate Cream, Solution for Scars™ (combined with vitamin E and magnolia bark^g extract), InstaNatural^® Skin Repair Gel (combined with sea kelp bioferment, aloe extract, and Gotu kola extract)
Resveratrol	N/A
Emodin	Jiashitang scar removal ointment (combined with safflower extract, red sage^h extract, and Sanchi ginsengⁱ extract)
Curcumin	Kayos^TM Curcumin Cream (combined with vitamin E), Thorakao Curcuma Cream

Abbreviations: N/A, not available.

= Tamarindus indica L., ^b= Phyllanthus emblica L., ^c= Broussonetia papyrifera (L.) L'Hér. ex Vent., ^d= Theobroma cacao L., ^e= Carthamus tinctorius L., ^f= Bulbine frutescens (L.) Willd., ^g= Magnolia officinalis Rehder & E.H.Wilson, ^h= Salvia miltiorrhiza Bunge, ⁱ= Panax notoginseng (Burkill) F.H.Chen.

Onion

Onion extract is one of the most frequently used constituents in nonprescription scar treatment products. The active ingredients in onion extract are the flavonoids quercetin and kaempferol, which demonstrate anti-inflammatory, antioxidant, antibacterial, antiproliferative, and collagen downregulatory properties.^5,17-21 Onion extract and quercetin have been shown to induce the upregulation of MMP-1 expression in vitro and in vivo studies, which is vital for ECM remodeling during wound healing.²² Thus, this agent may play an antifibrotic role. In addition, quercetin has been demonstrated in vitro to suppress the TGF-β/Smad and insulin-like growth factor-I (IGF-I) signaling pathways.^23,24 TGF-β/Smad and IGF-I signalings are known to have a role in pathologic fibroproliferation and abnormal scar formation. Thus, onion extract is a promising anti-scarring agent.

In this review, 11 clinical trials were identified in the current literature regarding the efficacy of onion extract on scars.^25-35 The evidence was found to be inconsistent (Table 3). Four of these studies were ranked as level of evidence 1b,^26-28,35 and the rest were ranked as level 2b. Some clinical trials of onion extract reported positive experiences with scar appearance. The randomized, single-blinded split scar study of an onion extract patch containing allantoin versus no treatment on post-dermatologic surgery scars (n = 124) found that the overall appearance and cosmesis were significantly better in the treatment group, as assessed by the Global Aesthetic Improvement Scale (GAIS) and Patient and Observer Scar Assessment Scale (POSAS).²⁵ The double-blinded RCT by Song et al (n = 90) comparing onion extract gel with silicone gel to treat postsurgical scars concluded that both had more efficacy than the untreated control, improving the overall appearance and cosmetic satisfaction.²⁶ However, the onion extract gel and silicone gel had similar efficacy. Two randomized studies by Jenwitheesuk et al in 2012 (n = 54)²⁷ and Wananukul et al in 2013 (n = 30),²⁸ following median sternotomy incision, concluded that onion extract in silicone derivative gel was more effective than placebo gel, with respect to hypertrophic scars incidence, scar pigmentation, and scar symptoms.

In some studies, it was concluded that combining onion extract with other therapies had a more remarkable improvement in scar conditions than individual treatment. The randomized comparative study of hypertrophic and keloid scars by Hosnuter et al (n = 60) concluded that a combination of onion extract gel with silicone gel sheet was the most effective therapeutic agent in improving scar appearance and symptoms, especially for scar height.²⁹ Another randomized, controlled, comparative study evaluating 27 patients with hypertrophic scars or keloids showed that a combination of intralesional triamcinolone acetonide (TAC) and onion extract gel was superior to TAC alone concerning pain or sensitiveness, elevation, and itching; however, not in erythema and induration.³⁰

Some clinical trials of onion extract on scar management gave neutral or negative findings compared to other commonly used topical treatments. In a double-blinded RCT of onion extract gel compared with silicone gel in patients with postsurgical upper extremity wounds (n = 107), Hassanpour et al concluded no significant difference in vascularity, pliability, pigmentation, and height, as subjectively assessed using the Vancouver Scar Scale (VSS).³¹ However, in an RCT of 45 patients with postburn hypertrophic scars, Karagoz et al reported that both silicone gel and silicone gel sheet were significantly more effective than onion extract in improving cosmesis by using the VSS.³² Other studies utilizing onion extract gel following Mohs surgery (n = 24)³³ and upper blepharoplasty (n = 43)³⁴ all showed no significant difference in scar cosmesis between topical onion extract and petroleum emollient. However, some of the possible limitations were that all patients were elderly Caucasians,³³ and the studied surgical sites were eyelids,³⁴ which are considered low-risk for scar formation. Another double-blinded comparative study comparing onion extract, topical steroid, and petrolatum emollient also showed no significant difference regarding scar appearance after upper blepharoplasty.³⁵ However, the follow-up time of this study was only 3 months, which may need to be longer to observe clinically evident effects.

In summary, according to the review of published studies, onion extract was superior to no treatment, but was not superior to other scar management treatments. Onion extract may be most effective when used in combination with other therapies. In terms of the safety of onion extract, there have been reported mild to moderate adverse reactions in human studies, including itching, burning, skin irritation, and contact dermatitis; however, they have resolved spontaneously.^25,26,29,34

Vitamin E

Vitamin E, an essential micronutrient with lipid-soluble antioxidants, consists of tocopherols and tocotrienols.^36,37 Vitamin E is a plant-derived compound. Green leafy vegetables, vegetable oils, nuts, and seeds are good vitamin E sources.³⁸ The possible mechanism of action of vitamin E on scar management involves the anti-inflammation effect and the inhibitory effects on fibroblast proliferation and collagen synthesis.^37,39-41 Additionally, the antioxidant effect may prevent scar formation by decreasing cell damage from free oxygen radicals available during the inflammatory phase and preventing lipid peroxidation in membranes. Therefore, vitamin E acts as a cellular membrane-stabilizing agent.^41-44

Vitamin E has been primarily used in cosmetics and in treating acute and chronic dermal wounds.^37,45 Though many patients and medical professionals believe that vitamin E may promote wound healing and improve scar cosmesis, there is little scientific evidence supporting these claims.^46,47 Four clinical trials were considered in this study, all of which were classified as level of evidence 2b.^47-50 A double-blinded RCT of 15 patients undergoing Mohs surgery demonstrated that a petrolatum-based ointment containing vitamin E did not improve scar cosmetic appearance compared to the petrolatum-based ointment alone.⁴⁷ Furthermore, almost a third of patients developed contact dermatitis to the treatment with ointment containing vitamin E. In a double-blinded, randomized, placebo-controlled trial on 85 patients with surgical scars less than 2-week-old, 5% topical tocotrienol showed no significant effect on any of the scar parameters using laser Doppler imaging (LDI), POSAS, and a photographic scar assessment by a visual analogue scale (VAS) at 4-month follow-up.⁴⁸

In contrast, a large-scale, single-blinded RCT by Zampieri et al (n = 428) evaluated the before-and-after use of vitamin E on pediatric patients undergoing inguinal surgery.⁴⁹ Treatment with topical vitamin E provided a significant enhancement in cosmetic scar appearance as assessed by VSS and a significantly lower incidence of keloid formation. However, it is worth mentioning that the study population consisted of Caucasian children aged between 2–9 years old, who are less prone to develop keloids. This could also potentially limit the generalizability of this study's findings to the adult population. Similarly, an RCT conducted by Palmieri et al (n = 80) found a significant improvement in scar symptoms (pain and itching), color, size, and cosmetic appearance for keloid and hypertrophic scars treated with a combining vitamin E and silicone gel sheeting compared to the silicone gel sheeting alone.⁵⁰ This study concluded that combining vitamin E and silicone gel sheeting is efficacious for scar treatment, probably due to a sequential synergistic effect.

In summary, the current scientific evidence still lacks strong support for improving scar appearance with topical vitamin E alone. In addition, several side effects, such as contact dermatitis,^47,51-53 urticarial eruptions,⁵² and erythema multiforme-like reaction,^52,54 possibly worsening scars, have been reported following its use. The early use of vitamin E in scar treatment may also reduce wound tensile strength due to its ability to inhibit collagen production, which could result in wound dehiscence and widened scars.⁵⁵ The topical application of vitamin E should thereby be discouraged. Further investigations of vitamin E used alone and/or in combination therapy are needed to confirm its clinical application in scar management.

Gotu Kola

C. asiatica, also commonly known as Gotu kola, is a medicinal plant used in both Asian traditional medicine and Western medicine. It has traditionally been used for wound healing promotion, scar reduction, and anti-inflammation. Pentacyclic triterpenes are active compounds, primarily asiaticoside, madecassoside, asiatic acid, and madecassic acid.^56-58 Madecassoside has been reported to diminish scar formation by inhibiting keloid scar-derived fibroblast (KF) proliferation, inducing KF apoptosis by a mitochondrial-dependent pathway,⁵⁹ and inhibiting KF migration.⁶⁰ Of the other active components, both asiaticoside and asiatic acid have been demonstrated in vitro and in vivo studies to suppress KF proliferation and collagen synthesis by inducing Smad7 expression and inhibiting TGF-βI and TGF-βII expression, thus blocking the TGF-β/Smad signaling pathway.^61-63 Gotu kola could therefore be of great use in preventing and treating scar formation.

Following the literature search, six articles were considered.^64-69 Of these, just two were ranked as level of evidence 1b,^65,69 and the remainder were ranked as level 2b. In clinical trials, the local application of Gotu kola extract has been demonstrated to have beneficial effects in reducing re-epithelialization and the complete wound healing time, as well as improving the wound appearance in patients with partial-thickness burn wounds (n = 60)⁶⁴ and facial acne scars underwent laser treatment (n = 30).⁶⁵ The oral administration of Gotu kola extract has been demonstrated to improve wound healing in diabetic foot ulcer patients due to fast wound contraction compared to placebo (n = 170).⁶⁶ It has also been shown to suppress scar formation due to a significant change in the granulation tissue formed between the study and placebo groups. A limited number of studies have shown that Gotu kola could be efficacious in scar management. The randomized, double-blinded, split-scar study utilizing Gotu kola alcoholic extract cream following a split-thickness skin graft (STSG) operation (n = 23) indicated a significant improvement in pigmentation and overall VSS scores between 4 and 12 weeks.⁶⁷ Two studies concluded that combining Gotu kola with herbal extracts gel could be beneficial in scar prevention and amelioration. The first, a randomized split-scar trial in patients with postsurgical wounds (n = 17), demonstrated that the combination of polyherbs with Gotu kola effectively improved scar appearance and hyperpigmentation, as evaluated using the POSAS.⁶⁸ The second, an RCT combining Gotu kola with herbal extracts gel plus silicone gel compared with placebo gel for the scar prevention of median sternotomy wounds (n = 46), indicated that the scarring in the study group was better in all items of the VSS, especially in scar height and pliability.⁶⁹ However, it is hard to determine the efficacy of this treatment regimen to Gotu kola extract alone, because silicone gel and the other combined herbal extracts, such as onion extract and aloe (Aloe vera (L.) Burm.f.) extract, have been independently demonstrated to improve scar cosmetic appearance.

In conclusion, although many preclinical studies have shown the therapeutic potential of Gotu kola with respect to scar prevention and amelioration, clinical evidence is sparse. A few clinical trials have demonstrated a trend effect in relation to the application of Gotu kola in scar management, but the small sample size and insufficient information on the herbal preparation used are inadequate to substantiate a well-established use. Therefore, more research is needed to clarify its therapeutic efficacy for scar prevention and treatment. In terms of the safety of Gotu kola, possible side effects occur less frequently, but it may lead to gastrointestinal system disorders, including abdominal pain, flatulence, constipation, dry mouth, nausea, and vomiting, when used orally. The topical application of Gotu kola may result in allergic reactions and a burning sensation.⁷⁰ Allergic contact dermatitis has also been indicated in a few case-reports following topical application;^71-73 however, further evaluation disclosed that this reaction might have been caused by other ingredients in the products.⁷⁴ Due to little or no information being available regarding its safety during pregnancy and lactation, the use of Gotu kola is not recommended during these periods.^57,70

Green Tea

Green tea, produced from the C. sinensis leaves, is one of the most widely consumed beverages. Its polyphenolic catechins, including (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin-3-gallate (ECG), and (-)-epigallocatechin-3-gallate (EGCG), have natural healing, photoprotective, free radical scavenging, antioxidant, anti-inflammatory, and antibacterial activities.^75,76 EGCG, the most abundant green tea catechins, has shown a potential therapeutic effect in wounds and fibrosis/scarring. In KF cultures, EGCG has been demonstrated to suppress mast cell-stimulated collagen type I production by blocking the PI3K/Akt signaling pathway.^77,78 EGCG has also been demonstrated to suppress the proliferation, migration, and collagen synthesis in KFs by disrupting the signal transducer and activator of transcription-3 (STAT3) signaling pathway.^78,79 In the fibroblast-populated collagen lattice (FPCL) model, EGCG has been shown to inhibit PDGF- and TGF-βI-stimulated collagen gel contraction.^80-82 It directly interacts with PDGF-BB, blocking its specific receptor binding and thereby inhibiting cell proliferation and collagen contraction.^80,81 Furthermore, EGCG has been demonstrated to interrupt TGF-β signaling in some cell types by inhibiting the gene expression of TGF-β type I and II receptors, resulting in reduced CTGF and ECM gene expression.^83,84 All of these profibrotic pathways, including TGF-βI, TGF-βII, PDGF, CTGF, PI3K/Akt, and STAT3, play an essential role in fibrosis/scarring.

Several studies on animal models have demonstrated the beneficial effects of polyphenolic catechins, especially ECG and EGCG, in wound healing and scarring^84-87; nonetheless, little clinical trial has been performed on their potential for scar management. An RCT (n = 62) ranked as level of evidence 1b compared the topical administration of EGCG with placebo on the area surrounding a wound (zonal priming) and the fully formed scar.⁸⁸ Both systems of the topical EGCG were more effective than the placebo at improving scar thickness, elasticity, redness, and skin hydration.

Based on the present findings, there is inadequate evidence supporting the beneficial effect of the clinical application of EGCG on scarring. More clinical research needs to substantiate the anti-scarring effect of EGCG. In terms of safety, EGCG is classified as a “generally recognized as safe (GRAS)” substance by the United States Food and Drug Administration (USFDA).⁸⁹ It appears well tolerated with oral^90-93 and topical administration^94,95 in human studies. The most frequently reported adverse events are mild gastrointestinal issues, including abdominal pain/discomfort and nausea.^90,92,93 Nevertheless, the clinical application of EGCG has some limitations because of its low bioavailability.⁷⁵ Therefore, topical or intralesional administration might be a more effective route to accomplish the functionality of EGCG. It is also unstable under high temperature and pH conditions, which could be a problem for developing dermatological and cosmetic products.⁹⁶

Resveratrol

Resveratrol, a natural plant polyphenolic compound, is abundantly present in grapes (Vitis vinifera L.) skin and seeds, red wine, peanuts, and soy. It is known to have numerous biological effects and pharmacological actions, such as antioxidant, anti-inflammatory, photoprotective, anti-aging, anticancer, and cardiovascular properties.^97-99 There is also growing evidence that resveratrol has a beneficial effect against pathological scars. At the cellular level, Zeng et al demonstrated that resveratrol treatment suppressed cell proliferation in hypertrophic scar-derived fibroblasts (HSFs) by arresting the G₁-phase cell cycle and inducing apoptosis.⁹⁸ Resveratrol further decreased the mRNA expression of procollagen type I and III in HSFs, reducing collagen deposition.⁹⁸ Zhai et al showed that resveratrol inhibited proliferation and triggered apoptosis in pathological scar-derived fibroblasts (PSFs) by altering the TGF-βI/Smad signaling pathway.¹⁰⁰ Ikeda et al reported similar findings regarding the proliferation inhibition and the apoptosis induction of KFs by resveratrol.^99,101 Pang et al discovered that resveratrol induced HSF autophagy by upregulating microRNA-4654 expression, leading to the downregulation of Ras homolog enriched in brain (Rheb).¹⁰² MicroRNA-4654 is known to regulate cell proliferation, differentiation, apoptosis, and autophagy, by directly binding to the GTP-binding protein Rheb, a target gene of microRNA-4654.¹⁰² In addition to TGF-βI/Smad signaling and the microRNA-4654/Rheb axis, the mammalian target of the rapamycin (mTOR)/ribosomal protein S6 kinase (70S6K) signaling pathway also seems to be pivotal in PSF proliferation.¹⁰³ The mRNA and protein expression of mTOR and 70S6K was downregulated by resveratrol, leading to the inhibition of PSF proliferation.¹⁰³ Resveratrol has also been shown to upregulate sirtuin1 (SIRT1) in HSFs, resulting in the suppression of TGF-βI-induced dermal fibroblast transition, and the reduction in the expression of fibrotic markers such as collagen type I, collagen type III, and α-SMA.¹⁰⁴ Resveratrol further improved collagen density and arrangement in a mouse model of excisional wound healing.¹⁰⁴ Similar to the study by Ma et al, an RCT on women with a scarred uterus (n = 78) (ranked as level of evidence 2b) showed that oral resveratrol treatment promoted scar remodeling and reduced uterine-scar thickness compared to the placebo at 3 months post-treatment.¹⁰⁵

From these findings, it could therefore be concluded that resveratrol might be a potential therapeutic agent to counteract excessive scarring. Although the anti-scarring effects of resveratrol have been reported in numerous preclinical studies within various targets, further animal and clinical research is necessary to confirm these resveratrol-associated effects. Currently there is, to the best of our knowledge, only one published clinical trial regarding the anti-scarring properties of resveratrol. An obstacle that has limited the clinical administration of resveratrol is its fast metabolization and excretion.⁹⁷ Hence, improving its bioavailability during systemic intake or developing appropriate formulations for local and topical use is a subject of substantial research and may help in the targeted delivery of resveratrol.

Emodin

Emodin, a natural anthraquinone derivative, is found in numerous Chinese herbs, such as rhubarb (Rheum palmatum L.), Japanese knotweed (Polygonum cuspidatum Siebold & Zucc.), and Chinese climbing knotweed (Polygonum multiflorum Thunb.). It has been reported to exert various biological effects, including antiviral, antibacterial, anticancer, immunosuppressive, anti-inflammatory, anti-allergic, and wound-healing effects.^106-108 Previous preclinical studies have shown that emodin inhibits fibrotic activity in many organs, suggesting that it might be beneficial in fibrosis treatment.^109-112 Nevertheless, there are few studies examining the efficacy of emodin in treating hypertrophic scars.

Liu showed that emodin inhibited inflammation in mechanical stress-induced hypertrophic scar by suppressing the recruitment and adhesion of inflammatory cells and attenuating the synthesis of inflammatory cytokines, which are associated with the suppression of the PI3K/Akt signaling pathway.¹¹³ Furthermore, Xia et al demonstrated that emodin inhibited hypertrophic scar development and fibrosis by blocking macrophage recruitment and polarization, which is related to suppressing the TGF-β and Notch signaling pathways in macrophages.¹¹⁴ Taken together, these findings suggest a potential positive effect of emodin on hypertrophic scars. However, whether emodin can be clinically used as a therapeutic agent for hypertrophic scar treatment remains uncertain. Thus, more research, especially clinical trials, is imperative to evaluate the therapeutic use of emodin.

Regarding the adverse effects of emodin, its toxicity, including reproductive toxicity, hepatotoxicity, and nephrotoxicity, has been reported among preclinical experiments, especially in high doses and prolonged use.¹⁰⁶ Another issue is that emodin has low absorption in the intestine, rapid elimination, and poor oral bioavailability in vivo.¹⁰⁶ Further research is thereby required to attenuate its toxicity and improve its pharmacokinetics.

Curcumin

Curcumin, a yellow polyphenolic compound derived from turmeric (Curcuma longa L.) rhizome and the most active constituent of turmeric, has been used extensively in Ayurvedic medicine. It has been shown to possess several biological activities, including anti-inflammatory, antioxidant, antimicrobial, anticarcinogenic, anticoagulant, and antithrombotic activities. Curcumin has also been demonstrated to possess wound healing activity by acting on various phases of wound healing.^115-117 Furthermore, it has been shown to possess a potent antifibrotic effect.^118-121 Even though there are many in vitro and in vivo studies reporting curcumin's role in fibrosis prevention and reduction, there are few reports on its effects on scarring.

Scharstuhl et al demonstrated that curcumin treatment in a high dose (>25 μM) induced apoptosis in human dermal fibroblasts and inhibited collagen gel contraction mediated by fibroblasts through a reactive oxygen species (ROS)-mediated mechanism.¹²² Meanwhile, Phan et al demonstrated that curcumin inhibited KF and HSF proliferation by inducing cell cycle arrest and collagen lattice contraction in HSFs.¹⁷ Curcumin has also been found to inhibit the TGF-βI/Smad signaling pathway and ECM synthesis in KFs.¹²³ In a rabbit ear hypertrophic scar model, curcumin suppressed hypertrophic scarring by reducing the release of inflammatory cytokines IL-1, IL-6, and IL-8.¹²⁴ The results of this series of studies led to the conclusion that curcumin may promise to be a potential therapeutic agent for pathological scarring. However, there is still a lack of documented clinical trials. Further clinical research is required to confirm its efficacy and safety on scarring.

Unfortunately, curcumin's clinical application is limited because of its poor water solubility, poor absorption, fast metabolism, fast elimination, poor bioavailability, photosensitivity, and yellow staining on the skin and clothes.^115,116 Novel formulations should be explored to minimize these effects and maximize curcumin's therapeutic capability. In terms of the safety of curcumin, it has been approved by the USFDA as “GRAS”.¹¹⁶ Curcumin is well tolerated and non or low toxic. The most commonly reported adverse events are nausea and diarrhea when used orally; however, they resolve spontaneously after 1 to 3 days.¹²⁵

Others

In recent years, there has been a steady global increase in the use of natural products, accompanied by a growing search for new phytochemicals that could potentially be developed as antihypertrophic scar agents.^11,12,126 Nowadays, other emerging natural products, such as oleanolic acid (from the green leaf galls of Ligustrum lucidum W.T.Aiton and Prunella vulgaris L.),^127-130 shikonin (from the dried root of Zicao or Lithospermum erythrorhizon Siebold & Zucc),^131-134 glabridin (from Glycyrrhiza glabra L.),^135,136 tripterine (from Thunder God Vine or Tripterygium wilfordii Hook.f.),^137,138 and hyperforin (from Hypericum perforatum L.)^139-141 have been shown to have anti-scarring properties in various in vitro and in vivo models. However, to the best of our knowledge, these compounds or herbal extracts have not been found for their efficacy and safety in RCTs. Further well-designed clinical trials are required to confirm their potential effects as a lead compound or active ingredient for anti-scar preparations. In another way, traditional medicines have been reinvestigated for their potential effects on scar management. For example, Wubeizi ointment (a traditional Chinese medicine), which consists of Chinese herbs Salvia miltiorrhiza Bunge, Clematis spp., black vinegar, Galla Chinensis (gall produced by the aphid Melaphis chinensis), Cortex Lycii (root of Lycium chinense Mill.), and alum, has been reported to diminish scar formation by downregulating type I and III procollagen expressions, inhibiting fibroblast proliferation, and promoting fibroblast apoptosis.^142-145 Moreover, Saireito (a Japanese herbal (Kampo) medicine, a combined formulation of two herbal medicines, Shosaikoto and Goreisan) has shown beneficial effects in scar management by suppressing TGF-I-induced Smad2/3 phosphorylation.^146-149 These natural products should be further investigated to ensure their beneficial effect on scars and they might become potential anti-scarring agents in the future.

Discussion

This review article gathered publications on the role and mechanism of some natural products in scar prevention and treatment, particularly hypertrophic scars. It also addressed whether scar management with these natural products is effective in humans, thus providing a reference for the further research and development of natural product-based drugs for scar therapy with greater efficacy and lower side effects. In this review, a number of natural products, including onion, vitamin E, Gotu kola, green tea, resveratrol, emodin, curcumin, and other emerging natural products, have displayed potential effects as effective anti-scarring agents in preclinical studies. The main mechanisms of these natural products on scar formation involve inhibiting scar fibroblast proliferation and collagen production and/or inducing cell apoptosis by regulating several pathways, such as the TGF-β/Smad, MAPK, and PI3K/Akt signaling pathways (Table 2). Although these natural products have been reported to have potential anti-scarring activity in preclinical trials, this is not enough to substantiate their efficacy and safety in humans due to their different physiological structures. Therefore, clinical trials are essential to ascertain these natural products’ efficacy and safety as anti-scarring agents.

A total of 23 clinical trials using natural products as interventions for scar management were identified in this review. Among these 23 trials, only 3 RCTs recruited patients during the wound healing process (surgical wound, burn wound, and diabetic foot ulcer).^49,64,66 However, these 3 trials also evaluated the final outcome for scar management using the VSS, a 4-point scale for cosmetic appearance satisfaction, and scar formation. The natural products used in these 23 trials included 11 onion trials, 4 vitamin E trials, 6 Gotu kola trials, 1 green tea trial, and 1 resveratrol trial. Unfortunately, documented clinical trials are still lacking for both emodin and curcumin. Most clinical trials were categorized as level of evidence 2b (n = 16). Based on the existing evidence discussed in this review, even though some success has been shown in addressing specific aspects of scarring when these natural products are utilized as monotherapy or as combination therapy with other agents, there is limited evidence from clinical studies to support their efficacy due to the limited quality of the studies and their individual flaws, including small sample sizes, poor randomization and blinding, and short follow-up durations. These limitations imply that the existing evidence may not be sufficiently robust to support natural products’ efficacy and safety for clinical treatment and prevention of hypertrophic scars. The interpretation and clinical application of these results should be performed with caution. In terms of safety, while considered natural, some natural products have been associated with mild adverse events in human studies (such as onion, vitamin E, and Gotu kola; Table 3). However, limited data on toxicity is discussed in this review.

It is challenging to compare the natural product-based therapeutics among the studies owing to the various models and methodologies used to investigate the efficacy of these anti-scarring agents. Moreover, the variation in wound type and depth, anatomical location, age and type of scars, history of pathologic scarring, patient age, underlying health conditions, control groups (such as petrolatum ointment or no treatment), and follow-up and scar treatment periods among the clinical trials conducted make it difficult to directly compare agents between studies. Most studies identified in this review had follow-up periods less than or equal to 6 months. Ideally, the follow-up periods in scar studies should be at least 1 year to ascertain that the observed effect is a result of the treatment and not a spontaneous wound healing process that improves over time. The studies also varied in the scar assessment methods and the reported outcome measures. The scar assessment methods included objective scar assessments (noninvasive scar analysis techniques), such as LDI, and subjective scar assessment scales, such as VSS and POSAS. However, there is no standardized and universally accepted method to evaluate scars. Each scar scale assesses a different set of parameters with various criteria and frequently depends on individual investigators’ subjective interpretation, leading to problems in comparing multiple scar studies.

Among the 7 natural products for scar management reviewed, 5 demonstrated a positive impact on scar prevention and treatment, supported by RCTs. When compared in terms of the number and quality of trials, onion extract had the most RCTs (11) with the highest quality evidence (4 RCTs rated 1b and 7 RCTs rated 2b). This was followed by Gotu kola, which had 6 RCTs (2 rated 1b and 4 rated 2b); vitamin E, which had 4 RCTs (all rated 2b); green tea, which had 1 RCT (rated 1b); and resveratrol, which had 1 RCT (rated 2b). Each natural product exhibited different mechanisms of action for scar management, suggesting that a combination of various active ingredients or polyherbs may be the most suitable approach for developing anti-scar products.^68,146,150 Moreover, using standardized herbal extract, such as onion extract (which contains flavonoids, namely quercetin and kaempferol), which consists of numerous bioactive compounds, may be more advantageous than single pure compounds (such as resveratrol or vitamin E), not only due to potential synergistic effects but also considering the cost of isolation and preparation.^151-153

In conclusion, more robust, consistent, and well-designed RCTs with large-scale and prolonged follow-up durations are needed to establish a firm conclusion concerning these natural products’ long-term efficacy and safety profiles. These trials should also focus on immature and mature scars in order to provide clinically relevant insights to make phytotherapy a promising approach for scar prevention and treatment. Additionally, some of these agents have some limitations in clinical use because of their low bioavailability (EGCG, resveratrol, emodin, and curcumin; Table 4). Therefore, it is necessary to improve their bioavailability during systemic intake or to develop suitable formulations for local and topical applications to minimize these effects and maximize their therapeutic capability.

Conclusion

In this review, a number of natural products, including onion, vitamin E, Gotu kola, green tea, resveratrol, emodin, curcumin, and other emerging natural products, have shown beneficial effects as potential anti-scarring agents in preclinical studies. The main mechanisms of these natural products on scar formation involve inhibiting scar fibroblast proliferation and collagen production and/or inducing cell apoptosis by regulating several pathways, such as the TGF-β/Smad, MAPK, and PI3K/Akt signaling pathways. However, there is limited evidence from clinical studies to support their efficacy due to the limited quality of the studies. More robust and well-designed clinical trials with large-scale and prolonged follow-up durations are needed.

Footnotes

Acknowledgments

The authors are grateful to the Thailand Research Fund through the Research and Researcher for Industry Programme (RRi) and the 90^th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund) for their support.

Author Contributions

TM: Conceptualization, Methodology, Formal analysis, Investigation, Writing – Original Draft, Writing – Review and Editing, Visualization, Project administration.

AA: Validation, Writing – Review and Editing, Supervision.

PA: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Writing – Review and Editing, Supervision, Funding acquisition.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical Approval

Not applicable.

Funding

The author disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Thailand Research Fund through the Research and Researcher for Industry Programme (RRi) [grant number PHD60I0068]; and the 90^th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund) [grant number GCUGR1125642013D].

ORCID iDs

Thunyaluk Meetam

Pornanong Aramwit

References

Al-Shaqsi

Al-Bulushi

. Cutaneous scar prevention and management: overview of current therapies. Sultan Qaboos Univ Med J. 2016;16(1):e3-e8. doi:https://doi.org/10.18295/squmj.2016.16.01.002

Gauglitz

Korting

Pavicic

Ruzicka

Jeschke

. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011;17(1–2):113-125. doi:https://doi.org/10.2119/molmed.2009.00153

Shirakami

Yamakawa

Hayashida

. Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence. Burns Trauma. 2020;8:tkz003. doi:https://doi.org/10.1093/burnst/tkz003

Mony

Harmon

Hess

Dorafshar

Shafikhani

. An Updated Review of Hypertrophic Scarring. Cells. 2023;12(5):678. doi:https://doi.org/10.3390/cells12050678

Block

Gosain

King

. Emerging therapies for scar prevention. Adv Wound Care (New Rochelle). 2015;4(10):607-614. doi:https://doi.org/10.1089/wound.2015.0646

Agyare

Asase

Lechtenberg

Niehues

Deters

Hensel

. An ethnopharmacological survey and in vitro confirmation of ethnopharmacological use of medicinal plants used for wound healing in Bosomtwi-Atwima-Kwanwoma area, Ghana. J Ethnopharmacol. 2009;125(3):393-403. doi:https://doi.org/10.1016/j.jep.2009.07.024

Agyare

Boakye

Bekoe

Hensel

Dapaah

Appiah

. Review: african medicinal plants with wound healing properties. J Ethnopharmacol. 2016;177:85-100. doi:https://doi.org/10.1016/j.jep.2015.11.008

Deshmukh

Fernandes

Atul

Toppo

. Wound healing activity of Calotropis gigantea root bark in rats. J Ethnopharmacol. 2009;125(1):178-181. doi:https://doi.org/10.1016/j.jep.2009.06.007

Patil

Kandhare

Bhise

. Pharmacological evaluation of ethanolic extract of Daucus carota Linn root formulated cream on wound healing using excision and incision wound model. Asian Pac J Trop Biomed. 2012;2(2):S646-S655. doi:https://doi.org/10.1016/S2221-1691(12)60290-1

10.

Jha

Sharma

Ganesh

. Antioxidant and wound healing potential of Pistia stratiotes L. Asian Pac J Trop Dis. 2012;2:S579-S584. doi:https://doi.org/10.1016/S2222-1808(12)60225-4

11.

Mehta

Branford

Rolfe

. The evidence for natural therapeutics as potential anti-scarring agents in burn-related scarring. Burns Trauma. 2016;4:15. doi:https://doi.org/10.1186/s41038-016-0040-1

12.

Wang

Chen

Rahman

Xin

Zhang

. Medicinal plants for the treatment of hypertrophic scars. Evid Based Complement Alternat Med. 2015;2015:101340. doi:https://doi.org/10.1155/2015/101340

13.

Phillips

Ball

Sackett

, et al. 2009. Oxford Centre for Evidence-Based Medicine: Levels of Evidence. Accessed November 29, 2022. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009.

14.

Howick

Chalmers

Glasziou

, et al. The Oxford Levels of Evidence 2. Accessed November 29, 2022. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence.

15.

Profyris

Tziotzios

Do Vale

. Cutaneous scarring: pathophysiology, molecular mechanisms, and scar reduction therapeutics part I. The molecular basis of scar formation. J Am Acad Dermatol. 2012;66(1):1-10; quiz 11-2. doi:https://doi.org/10.1016/j.jaad.2011.05.055

16.

Pratsinis

Kletsas

. 2 - Growth factors in fetal and adult wound healing. In: Ågren

, ed. Wound healing biomaterials. Woodhead Publishing; 2016:41-68.

17.

Phan

Sun

Bay

Chan

Lee

. Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar-derived fibroblasts in vitro: therapeutic implication for excessive scarring. J Trauma. 2003;54(6):1212-1224. doi:https://doi.org/10.1097/01.Ta.0000030630.72836.32

18.

Johri

Zutshi

Kameshwaran

Atal

. Effect of quercetin and Albizzia saponins on rat mast cell. Indian J Physiol Pharmacol. 1985;29(1):43-46.

19.

Kikuchi

Kadono

Takehara

. Effects of various growth factors and histamine on cultured keloid fibroblasts. Dermatology. 1995;190(1):4-8. doi:https://doi.org/10.1159/000246625

20.

Kupietzky

Levi-Schaffer

. The role of mast cell-derived histamine in the closure of an in vitro wound. Inflamm Res. 1996;45(4):176-180. doi:https://doi.org/10.1007/bf02285158

21.

Poetschke

Gauglitz

. Onion extract. In: Téot

Mustoe

Middelkoop

Gauglitz

22.

Cho

Lee

. Onion extract and quercetin induce matrix metalloproteinase-1 in vitro and in vivo. Int J Mol Med. 2010;25(3):347-352.

23.

Phan

Lim

Chan

Tan

Lee

Longaker

. Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: implications for the treatment of excessive scars. J Trauma. 2004;57(5):1032-1037. doi:https://doi.org/10.1097/01.ta.0000114087.46566.eb

24.

Phan

See

Tran

, et al. Suppression of insulin-like growth factor signalling pathway and collagen expression in keloid-derived fibroblasts by quercetin: its therapeutic potential use in the treatment and/or prevention of keloids. Br J Dermatol. 2003;148(3):544-552. doi:https://doi.org/10.1046/j.1365-2133.2003.05174.x

25.

Prager

Gauglitz

. Effectiveness and safety of an overnight patch containing Allium cepa extract and Allantoin for post-dermatologic surgery scars. Aesthetic Plast Surg. 2018;42(4):1144-1150. doi:https://doi.org/10.1007/s00266-018-1172-4

26.

Song

Kim

Lee

. Randomised comparison of silicone gel and onion extract gel for post-surgical scars. J Obstet Gynaecol. 2018;38(5):702-707. doi:https://doi.org/10.1080/01443615.2017.1400524

27.

Jenwitheesuk

Surakunprapha

Jenwitheesuk

Kuptarnond

Prathanee

Intanoo

. Role of silicone derivative plus onion extract gel in presternal hypertrophic scar protection: a prospective randomized, double blinded, controlled trial. Int Wound J. 2012;9(4):397-402. doi:https://doi.org/10.1111/j.1742-481X.2011.00898.x

28.

Wananukul

Chatpreodprai

Peongsujarit

Lertsapcharoen

. A prospective placebo-controlled study on the efficacy of onion extract in silicone derivative gel for the prevention of hypertrophic scar and keloid in median sternotomy wound in pediatric patients. J Med Assoc Thai. 2013;96(11):1428-1433.

29.

Hosnuter

Payasli

Isikdemir

Tekerekoglu

. The effects of onion extract on hypertrophic and keloid scars. J Wound Care. 2007;16(6):251-254. doi:https://doi.org/10.12968/jowc.2007.16.6.27070

30.

Koc

Arca

Surucu

Kurumlu

. An open, randomized, controlled, comparative study of the combined effect of intralesional triamcinolone acetonide and onion extract gel and intralesional triamcinolone acetonide alone in the treatment of hypertrophic scars and keloids. Dermatol Surg. 2008;34(11):1507-1514. doi:https://doi.org/10.1111/j.1524-4725.2008.34314.x

31.

Hassanpour

Farnoush

Karami

Makarem

. The effect of silicone gel versus contractubex gel on the upper-extremity postsurgical scars: a randomized, double-blinded, controlled trial. Med J Islam Repub Iran. 2020;34:146. doi:https://doi.org/10.34171/mjiri.34.146

32.

Karagoz

Yuksel

Ulkur

Evinc

. Comparison of efficacy of silicone gel, silicone gel sheeting, and topical onion extract including heparin and allantoin for the treatment of postburn hypertrophic scars. Burns. 2009;35(8):1097-1103. doi:https://doi.org/10.1016/j.burns.2009.06.206

33.

Chung

Kelley

Marra

Jiang

. Onion extract gel versus petrolatum emollient on new surgical scars: prospective double-blinded study. Dermatol Surg. 2006;32(2):193-197. doi:https://doi.org/10.1111/j.1524-4725.2006.32045.x

34.

Owji

Khademi

Khalili

. Effectiveness of topical onion extract gel in the cosmetic appearance of blepharoplasty scar. J Clin Aesthet Dermatol. 2018;11(10):31-35.

35.

Owji

Khalili

Khademi

Shirvani

Sadati

. Comparison of the effectiveness of onion extract, topical steroid, and petrolatum emollient in cosmetic appearance of upper blepharoplasty scar. J Curr Ophthalmol. 2020;32(4):408-413. doi:https://doi.org/10.4103/joco.Joco_39_20

36.

Tanaydin

Conings

Malyar

van der Hulst

van der Lei

. The role of topical vitamin E in scar management: a systematic review. Aesthet Surg J. 2016;36(8):959-965. doi:https://doi.org/10.1093/asj/sjw046

37.

Nair

Gorain

Pandey

, et al. Tocotrienol in the Treatment of Topical Wounds: recent Updates. Pharmaceutics. 2022;14(11):2479. doi:https://doi.org/10.3390/pharmaceutics14112479

38.

Thiele

Hsieh

Ekanayake-Mudiyanselage

. Vitamin E: critical review of its current use in cosmetic and clinical dermatology. Dermatol Surg. 2005;31(7 Pt 2):805-13; discussion 813. doi:https://doi.org/10.1111/j.1524-4725.2005.31724

39.

Haas

Boscoboinik

Mojon

Böhnke

Azzi

. Vitamin E inhibits proliferation of human Tenon's capsule fibroblasts in vitro. Ophthalmic Res. 1996;28(3):171-175. doi:https://doi.org/10.1159/000267899

40.

Satterfield

Taube

Kenney

. Effect of vitamin E on the production of collagen, DNA and fibronectin in keratocytes in vitro. Ophthalmic Res. 1988;20(4):227-231. doi:https://doi.org/10.1159/000266648

41.

Ehrlich

Tarver

Hunt

. Inhibitory effects of vitamin E on collagen synthesis and wound repair. Ann Surg. 1972;175(2):235-240. doi:https://doi.org/10.1097/00000658-197202000-00013

42.

Tanaka

Okada

Konishi

Tsuji

. The effect of reactive oxygen species on the biosynthesis of collagen and glycosaminoglycans in cultured human dermal fibroblasts. Arch Dermatol Res. 1993;285(6):352-355. doi:https://doi.org/10.1007/bf00371836

43.

Musalmah

Fairuz

Gapor

Ngah

. Effect of vitamin E on plasma malondialdehyde, antioxidant enzyme levels and the rates of wound closures during wound healing in normal and diabetic rats. Asia Pac J Clin Nutr. 2002;11(Suppl 7):S448-S451. doi:https://doi.org/10.1046/j.1440-6047.11.s.7.6.x

44.

Record

Dreosti

Konstantinopoulos

Buckley

. The influence of topical and systemic vitamin E on ultraviolet light-induced skin damage in hairless mice. Nutr Cancer. 1991;16(3-4):219-225. doi:https://doi.org/10.1080/01635589109514160

45.

Chen

Davidson

. Scar management: prevention and treatment strategies. Curr Opin Otolaryngol Head Neck Surg. 2005;13(4):242-247. doi:https://doi.org/10.1097/01.moo.0000170525.74264.f8

46.

Curran

Crealey

Sadadcharam

Fitzpatrick

O'Donnell

. Vitamin E: patterns of understanding, use, and prescription by health professionals and students at a university teaching hospital. Plast Reconstr Surg. 2006;118(1):248-252. doi:https://doi.org/10.1097/01.prs.0000221306.86450.c5

47.

Baumann

Spencer

. The effects of topical vitamin E on the cosmetic appearance of scars. Dermatol Surg. 1999;25(4):311-315. doi:https://doi.org/10.1046/j.1524-4725.1999.08223.x

48.

Khoo

Halim

Zakaria

Mat Saad

Lau

. A prospective, randomised, double-blinded trial to study the efficacy of topical tocotrienol in the prevention of hypertrophic scars. J Plast Reconstr Aesthet Surg. 2011;64(6):e137-e145. doi:https://doi.org/10.1016/j.bjps.2010.08.029

49.

Zampieri

Zuin

Burro

Ottolenghi

Camoglio

. A prospective study in children: Pre- and post-surgery use of vitamin E in surgical incisions. J Plast Reconstr Aesthet Surg. 2010;63(9):1474-1478. doi:https://doi.org/10.1016/j.bjps.2009.08.018

50.

Palmieri

Gozzi

Palmieri

. Vitamin E added silicone gel sheets for treatment of hypertrophic scars and keloids. Int J Dermatol. 1995;34(7):506-509. doi:https://doi.org/10.1111/j.1365-4362.1995.tb00628.x

51.

de Groot

Berretty

van Ginkel

den Hengst

van Ulsen

Weyland

. Allergic contact dermatitis from tocopheryl acetate in cosmetic creams. Contact Dermatitis. 1991;25(5):302-304. doi:https://doi.org/10.1111/j.1600-0536.1991.tb01878.x

52.

Fisher

. Three faces of vitamin E topical allergy. Cutis. 1991;48(4):272-274.

53.

Perrenoud

Homberger

Auderset

, et al. An epidemic outbreak of papular and follicular contact dermatitis to tocopheryl linoleate in cosmetics. Swiss contact dermatitis research group. Dermatology. 1994;189(3):225-233. doi:https://doi.org/10.1159/000246843

54.

Saperstein

Rapaport

Rietschel

. Topical vitamin E as a cause of erythema multiforme-like eruption. Arch Dermatol. 1984;120(7):906-908.

55.

Widgerow

Chait

Stals

. New innovations in scar management. Aesthetic Plast Surg. 2000;24(3):227-234. doi:https://doi.org/10.1007/s002660010038

56.

Bylka

Znajdek-Awiżeń

Studzińska-Sroka

Brzezińska

. Centella asiatica in cosmetology. Postepy Dermatol Alergol. 2013;30(1):46-49. doi:https://doi.org/10.5114/pdia.2013.33378

57.

Bylka

Znajdek-Awiżeń

Studzińska-Sroka

Dańczak-Pazdrowska

Brzezińska

. Centella asiatica in dermatology: an overview. Phytother Res. 2014;28(8):1117-1124. doi:https://doi.org/10.1002/ptr.5110

58.

Diniz

LRL

Calado

Duarte

ABS

de Sousa

. Centella asiatica and Its Metabolite Asiatic Acid: Wound Healing Effects and Therapeutic Potential. Metabolites. 2023;13(2):276. doi:https://doi.org/10.3390/metabo13020276

59.

Song

Dai

Bian

, et al. Madecassoside induces apoptosis of keloid fibroblasts via a mitochondrial-dependent pathway. Drug Dev Res. 2011;72(4):315-322.

60.

Song

, et al. Madecassoside suppresses migration of fibroblasts from keloids: Involvement of p38 kinase and PI3K signaling pathways. Burns. 2012;38(5):677-684. doi:https://doi.org/10.1016/j.burns.2011.12.017

61.

Tang

Zhu

Liang

, et al. Asiaticoside suppresses collagen expression and TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts. Arch Dermatol Res. 2011;303(8):563-572. doi:https://doi.org/10.1007/s00403-010-1114-8

62.

Ju-Lin

Shao-Hai

Tian-Zeng

, et al. Effect of asiaticoside on hypertrophic scar in the rabbit ear model. J Cutan Pathol. 2009;36(2):234-239. doi:https://doi.org/10.1111/j.1600-0560.2008.01015.x

63.

Bian

Zhang

, et al. Asiatic acid isolated from Centella asiatica inhibits TGF-β1-induced collagen expression in human keloid fibroblasts via PPAR-γ activation. Int J Biol Sci. 2013;9(10):1032-1042. doi:https://doi.org/10.7150/ijbs.7273

64.

Saeidinia

Keihanian

Lashkari

, et al. Partial-thickness burn wounds healing by topical treatment: a randomized controlled comparison between silver sulfadiazine and centiderm. Medicine (Baltimore). 2017;96(9):e6168. doi:https://doi.org/10.1097/md.0000000000006168

65.

Damkerngsuntorn

Rerknimitr

Panchaprateep

, et al. The effects of a standardized extract of Centella asiatica on postlaser resurfacing wound healing on the face: a split-face, double-blind, randomized, placebo-controlled trial. J Altern Complement Med. 2020;26(6):529-536. doi:https://doi.org/10.1089/acm.2019.0325

66.

Paocharoen

. The efficacy and side effects of oral Centella asiatica extract for wound healing promotion in diabetic wound patients. J Med Assoc Thai. 2010;93(Suppl 7):S166-S170.

67.

Jenwitheesuk

Rojsanga

Chowchuen

Surakunprapha

. A prospective randomized, controlled, double-blind trial of the efficacy using Centella cream for scar improvement. Evid Based Complement Alternat Med. 2018;2018:9525624. doi:https://doi.org/10.1155/2018/9525624

68.

Chuangsuwanich

Jongjamfa

. The efficacy of combined herbal extracts gel preparation in the prevention of postsurgical hypertrophic scar formation. Dermatol Ther (Heidelb). 2014;4(2):187-195. doi:https://doi.org/10.1007/s13555-014-0055-0

69.

Surakunprapha

Winaikosol

Chowchuen

Punyavong

Jenwitheesuk

. A prospective randomized double-blind study of silicone gel plus herbal extracts versus placebo in Pre-sternal hypertrophic scar prevention and amelioration. Heliyon. 2020;6(5):e03883. doi:https://doi.org/10.1016/j.heliyon.2020.e03883

70.

Gohil

Patel

Gajjar

. Pharmacological review on Centella asiatica: a potential herbal cure-all. Indian J Pharm Sci. 2010;72(5):546-556. doi:https://doi.org/10.4103/0250-474x.78519

71.

Gomes

Pereira

Vilarinho

Duarte Mda

Brito

. Contact dermatitis due to Centella asiatica. Contact Dermatitis. 2010;62(1):54-55. doi:https://doi.org/10.1111/j.1600-0536.2009.01651.x

72.

Eun

Lee

. Contact dermatitis due to madecassol. Contact Dermatitis. 1985;13(5):310-313. doi:https://doi.org/10.1111/j.1600-0536.1985.tb02584.x

73.

Izu

Aguirre

Gil

Díaz-Pérez

. Allergic contact dermatitis from a cream containing Centella asiatica extract. Contact Dermatitis. 1992;26(3):192-193. doi:https://doi.org/10.1111/j.1600-0536.1992.tb00291.x

74.

Hausen

. Centella asiatica (Indian pennywort), an effective therapeutic but a weak sensitizer. Contact Dermatitis. 1993;29(4):175-179. doi:https://doi.org/10.1111/j.1600-0536.1993.tb03532.x

75.

Zhong

, et al. Beneficial Effects of Green Tea EGCG on Skin Wound Healing: A Comprehensive Review. Molecules. 2021;26(20):6123. doi:https://doi.org/10.3390/molecules26206123

76.

Jones

Patel

Wilson

Wang

Ashack

. Complementary and alternative medicine treatments for common skin diseases: a systematic review and meta-analysis. JAAD Int. 2021;2:76-93. doi:https://doi.org/10.1016/j.jdin.2020.11.001

77.

Zhang

Kelly

Wang

, et al. Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signaling pathways. J Invest Dermatol. 2006;126(12):2607-2613. doi:https://doi.org/10.1038/sj.jid.5700472

78.

Syed

Bagabir

Paus

Bayat

. Ex vivo evaluation of antifibrotic compounds in skin scarring: EGCG and silencing of PAI-1 independently inhibit growth and induce keloid shrinkage. Lab Invest. 2013;93(8):946-960. doi:https://doi.org/10.1038/labinvest.2013.82

79.

Park

Yoon

Moon

, et al. Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. J Invest Dermatol. 2008;128(10):2429-2441. doi:https://doi.org/10.1038/jid.2008.103

80.

Suzuki

Hattori

Isemura

. Epigallocatechin-3-O-gallate inhibits fibroblast contraction of floating collagen gel: interaction between epigallocatechin-3-O-gallate and platelet derived growth factor. Biosci Biotechnol Biochem. 2004;68(8):1817-1820. doi:https://doi.org/10.1271/bbb.68.1817

81.

Weber

Neuhaus

Skach

, et al. Mechanisms of the inhibitory effects of epigallocatechin-3 gallate on platelet-derived growth factor-BB-induced cell signaling and mitogenesis. Faseb j. 2004;18(1):128-130. doi:https://doi.org/10.1096/fj.03-0007fje

82.

Klass

Branford

Grobbelaar

Rolfe

. The effect of epigallocatechin-3-gallate, a constituent of green tea, on transforming growth factor-beta1-stimulated wound contraction. Wound Repair Regen. 2010;18(1):80-88. doi:https://doi.org/10.1111/j.1524-475X.2009.00552.x

83.

Yumei

Zhou

Zheng

Chen

. The antifibrogenic effect of (-)-epigallocatechin gallate results from the induction of de novo synthesis of glutathione in passaged rat hepatic stellate cells. Lab Invest. 2006;86(7):697-709. doi:https://doi.org/10.1038/labinvest.3700425

84.

Song

Wang

Yang

, et al. EGCG Inhibits hypertrophic scar formation in a rabbit ear model. J Cosmet Dermatol. 2023;22(4):1382-1391. doi:https://doi.org/10.1111/jocd.15587

85.

Kapoor

Howard

Hall

Appleton

. Effects of epicatechin gallate on wound healing and scar formation in a full thickness incisional wound healing model in rats. Am J Pathol. 2004;165(1):299-307. doi:https://doi.org/10.1016/s0002-9440(10)63297-x

86.

McKelvey

Appleton

. Epicatechin gallate improves healing and reduces scar formation of incisional wounds in type 2 diabetes mellitus rat model. Wounds. 2012;24(3):55-57.

87.

Kim

Kawazoe

Han

, et al. Enhanced wound healing by an epigallocatechin gallate-incorporated collagen sponge in diabetic mice. Wound Repair Regen. 2008;16(5):714-720. doi:https://doi.org/10.1111/j.1524-475X.2008.00422.x

88.

Ud-Din

Foden

Mazhari

, et al. A double-blind, randomized trial shows the role of zonal priming and direct topical application of epigallocatechin-3-gallate in the modulation of cutaneous scarring in human skin. J Invest Dermatol. 2019;139(8):1680-1690.e16. doi:https://doi.org/10.1016/j.jid.2019.01.030

89.

Wei

. Tea as a functional food for oral health. Nutrition. 2002;18(5):443-444. doi:https://doi.org/10.1016/s0899-9007(02)00763-3

90.

Chow

Cai

Hakim

, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res. 2003;9(9):3312-3319.

91.

Kumar

Pow-Sang

Spiess

, et al. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016;7(43):70794-70802. doi:https://doi.org/10.18632/oncotarget.12222

92.

Joe

Schnoll-Sussman

Bresalier

, et al. Phase ib randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in patients with Barrett's esophagus. Cancer Prev Res (Phila). 2015;8(12):1131-1137. doi:https://doi.org/10.1158/1940-6207.Capr-14-0274-t

93.

Chen

Liu

Chiu

Hsu

. Therapeutic effect of high-dose green tea extract on weight reduction: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2016;35(3):592-599. doi:https://doi.org/10.1016/j.clnu.2015.05.003

94.

Zhao

Zhu

Jia

, et al. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy. Br J Radiol. 2016;89(1058):20150665. doi:https://doi.org/10.1259/bjr.20150665

95.

Zhu

Jia

Chen

, et al. Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy. Oncotarget. 2016;7(30):48607-48613. doi:https://doi.org/10.18632/oncotarget.9495

96.

Frasheri

Schielein

Tizek

Mikschl

Biedermann

Zink

. Great green tea ingredient? A narrative literature review on epigallocatechin gallate and its biophysical properties for topical use in dermatology. Phytother Res. 2020;34(9):2170-2179. doi:https://doi.org/10.1002/ptr.6670

97.

Hecker

Schellnegger

Hofmann

, et al. The impact of resveratrol on skin wound healing, scarring, and aging. Int Wound J. 2022;19(1):9-28. doi:https://doi.org/10.1111/iwj.13601

98.

Zeng

Zhong

Luo

Zhang

. Resveratrol-mediated reduction of collagen by inhibiting proliferation and producing apoptosis in human hypertrophic scar fibroblasts. Biosci Biotechnol Biochem. 2013;77(12):2389-2396. doi:https://doi.org/10.1271/bbb.130502

99.

Zhao

Zhu

Yang

Liang

. Resveratrol-loaded peptide-hydrogels inhibit scar formation in wound healing through suppressing inflammation. Regen Biomater. 2020;7(1):99-107. doi:https://doi.org/10.1093/rb/rbz041

100.

Zhai

Ding

Tang

. Resveratrol inhibits proliferation and induces apoptosis of pathological scar fibroblasts through the mechanism involving TGF-β1/Smads signaling pathway. Cell Biochem Biophys. 2015;71(3):1267-1272. doi:https://doi.org/10.1007/s12013-014-0317-6

101.

Ikeda

Torigoe

Matsumoto

Fujita

Sato

Yotsuyanagi

. Resveratrol inhibits fibrogenesis and induces apoptosis in keloid fibroblasts. Wound Repair Regen. 2013;21(4):616-623. doi:https://doi.org/10.1111/wrr.12062

102.

Pang

Tang

, et al. Resveratrol inhibits hypertrophic scars formation by activating autophagy via the miR-4654/Rheb axis. Mol Med Rep. 2020;22(4):3440-3452. doi:https://doi.org/10.3892/mmr.2020.11407

103.

Tang

Zhai

Ding

. Expression of mTOR/70S6K signaling pathway in pathological scar fibroblasts and the effects of resveratrol intervention. Mol Med Rep. 2017;15(5):2546-2550. doi:https://doi.org/10.3892/mmr.2017.6339

104.

Bai

Liu

Yang

, et al. Identification of sirtuin 1 as a promising therapeutic target for hypertrophic scars. Br J Pharmacol. 2016;173(10):1589-1601. doi:https://doi.org/10.1111/bph.13460

105.

Qiao

. Analysis of the efficacy of resveratrol treatment in patients with scarred uterus. Exp Ther Med. 2018;15(6):5410-5414. doi:https://doi.org/10.3892/etm.2018.6126

106.

Dong

Yin

, et al. Emodin: a review of its pharmacology, toxicity and pharmacokinetics. Phytother Res. 2016;30(8):1207-1218. doi:https://doi.org/10.1002/ptr.5631

107.

Semwal

Combrinck

Viljoen

. Emodin - A natural anthraquinone derivative with diverse pharmacological activities. Phytochemistry. 2021;190:112854. doi:https://doi.org/10.1016/j.phytochem.2021.112854

108.

Chen

Lin

Liu

, et al. Emodin accelerates diabetic wound healing by promoting anti-inflammatory macrophage polarization. Eur J Pharmacol. 2022;936:175329. doi:https://doi.org/10.1016/j.ejphar.2022.175329

109.

Chen

Sun

, et al. Inhibitory effect of emodin on bleomycin-induced pulmonary fibrosis in mice. Clin Exp Pharmacol Physiol. 2009;36(2):146-153. doi:https://doi.org/10.1111/j.1440-1681.2008.05048.x

110.

Dong

Jia

Zhang

, et al. Emodin protects rat liver from CCl(4)-induced fibrogenesis via inhibition of hepatic stellate cells activation. World J Gastroenterol. 2009;15(38):4753-4762. doi:https://doi.org/10.3748/wjg.15.4753

111.

Noor

Wong

, et al. In vitro anti-fibrotic activities of herbal compounds and herbs. Nephrol Dial Transplant. 2009;24(10):3033-3041. doi:https://doi.org/10.1093/ndt/gfp245

112.

Xiong

Chen

Wan

, et al. Emodin promotes fibroblast apoptosis and prevents epidural fibrosis through PERK pathway in rats. J Orthop Surg Res. 2019;14(1):319. doi:https://doi.org/10.1186/s13018-019-1357-9

113.

Liu

. Inhibition of mechanical stress-induced hypertrophic scar inflammation by emodin. Mol Med Rep. 2015;11(6):4087-4092. doi:https://doi.org/10.3892/mmr.2015.3265

114.

Xia

Wang

Yang

, et al. Emodin alleviates hypertrophic scar formation by suppressing macrophage polarization and inhibiting the Notch and TGF-β pathways in macrophages. Braz J Med Biol Res. 2021;54(8):e11184. doi:https://doi.org/10.1590/1414-431X2021e11184

115.

Akbik

Ghadiri

Chrzanowski

Rohanizadeh

. Curcumin as a wound healing agent. Life Sci. 2014;116(1):1-7. doi:https://doi.org/10.1016/j.lfs.2014.08.016

116.

Rathore

Mukim

Sharma

Devi

Nagar

Khalid

. Curcumin: a review for health benefits. Int J Res Rev. 2020;7(1):273-290.

117.

Vollono

Falconi

Gaziano

, et al. Potential of Curcumin in Skin Disorders. Nutrients. 2019;11(9):2169. doi:https://doi.org/10.3390/nu11092169

118.

Zhang

Gong

Wang

Ling

. Antifibrotic effect of curcumin in TGF-β 1-induced myofibroblasts from human oral mucosa. Asian Pac J Cancer Prev. 2012;13(1):289-294. doi:https://doi.org/10.7314/apjcp.2012.13.1.289

119.

Kuwabara

Tamada

Iwai

, et al. Attenuation of renal fibrosis by curcumin in rat obstructive nephropathy. Urology. 2006;67(2):440-446. doi:https://doi.org/10.1016/j.urology.2005.09.028

120.

Vizzutti

Provenzano

Galastri

, et al. Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest. 2010;90(1):104-115. doi:https://doi.org/10.1038/labinvest.2009.112

121.

Punithavathi

Venkatesan

Babu

. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol. 2000;131(2):169-172. doi:https://doi.org/10.1038/sj.bjp.0703578

122.

Scharstuhl

Mutsaers

Pennings

Szarek

Russel

Wagener

. Curcumin-induced fibroblast apoptosis and in vitro wound contraction are regulated by antioxidants and heme oxygenase: implications for scar formation. J Cell Mol Med. 2009;13(4):712-725. doi:https://doi.org/10.1111/j.1582-4934.2008.00339.x

123.

Hsu

Chen

Chang

. Suppression of TGF-β1/SMAD pathway and extracellular matrix production in primary keloid fibroblasts by curcuminoids: its potential therapeutic use in the chemoprevention of keloid. Arch Dermatol Res. 2010;302(10):717-724. doi:https://doi.org/10.1007/s00403-010-1075-y

124.

Jia

Xie

Hong

, et al. Intravenous curcumin efficacy on healing and scar formation in rabbit ear wounds under nonischemic, ischemic, and ischemia-reperfusion conditions. Wound Repair Regen. 2014;22(6):730-739. doi:https://doi.org/10.1111/wrr.12231

125.

Asher

Spelman

. Clinical utility of curcumin extract. Altern Ther Health Med. 2013;19(2):20-22.

126.

Murakami

Shigeki

. Pharmacotherapy for Keloids and Hypertrophic Scars. Int J Mol Sci. 2024;25(9):4674. doi:https://doi.org/10.3390/ijms25094674

127.

Luo

Wang

Yuan

Jin

. Oleanolic acid regulates the proliferation and extracellular matrix of keloid fibroblasts by mediating the TGF-β1/SMAD signaling pathway. J Cosmet Dermatol. 2023;22(7):2083-2089. doi:https://doi.org/10.1111/jocd.15673

128.

Zhao

Luan

. Oleanolic acid attenuates renal fibrosis through TGF-β/Smad pathway in a rat model of unilateral ureteral obstruction. Evid Based Complement Alternat Med. 2020;2020:2085303. doi:https://doi.org/10.1155/2020/2085303

129.

Lin

Wen

Sun

. Oleanolic acid derivatives for pharmaceutical use: a patent review. Expert Opin Ther Pat. 2016;26(6):643-655. doi:https://doi.org/10.1080/13543776.2016.1182988

130.

Chen

Zhang

Qin

. Triggering of p38 MAPK and JNK signaling is important for oleanolic acid-induced apoptosis via the mitochondrial death pathway in hypertrophic scar fibroblasts. Phytother Res. 2014;28(10):1468-1478. doi:https://doi.org/10.1002/ptr.5150

131.

Zhang

Wang

Deng

, et al. Shikonin promotes hypertrophic scar repair by autophagy of hypertrophic scar-derived fibroblasts. Acta Cir Bras. 2023;38:e384623. doi:https://doi.org/10.1590/acb384623

132.

Ning

Wiraja

Chew

WTS

Fan

. Transdermal delivery of Chinese herbal medicine extract using dissolvable microneedles for hypertrophic scar treatment. Acta Pharm Sin B. 2021;11(9):2937-2944. doi:https://doi.org/10.1016/j.apsb.2021.03.016

133.

Vinaik

Barayan

Auger

Abdullahi

Jeschke

. Regulation of glycolysis and the Warburg effect in wound healing. JCI Insight. 2020;5(17):e138949. doi:https://doi.org/10.1172/jci.insight.138949

134.

Fan

Dong

Xie

, et al. Shikonin reduces TGF-β1-induced collagen production and contraction in hypertrophic scar-derived human skin fibroblasts. Int J Mol Med. 2015;36(4):985-991. doi:https://doi.org/10.3892/ijmm.2015.2299

135.

Zhang

Qian

Tang

, et al. Glabridin from Glycyrrhiza glabra possesses a therapeutic role against keloid via attenuating PI3K/Akt and transforming growth factor-β1/SMAD signaling pathways. J Agric Food Chem. 2022;70(35):10782-10793. doi:https://doi.org/10.1021/acs.jafc.2c02045

136.

, et al. Simultaneous deactivation of FAK and src improves the pathology of hypertrophic scar. Sci Rep. 2016;6:26023. doi:https://doi.org/10.1038/srep26023

137.

Huang

Zhang

Lei

Yan

Xue

. Tripterine inhibits proliferation and promotes apoptosis of keloid fibroblasts by targeting ROS/JNK signaling. J Burn Care Res. 2024;45(1):104-111. doi:https://doi.org/10.1093/jbcr/irad106

138.

Jiang

Sun

Wang

. Tripterine emerges as a potential anti-scarring agent in NIH/3T3 cells by repressing ANRIL. Gen Physiol Biophys. 2020;39(4):355-362. doi:https://doi.org/10.4149/gpb_2019050

139.

Yalcınkaya

Basaran

Tunckasık

Yazici

Elmas

Kocaturk

. Efficiency of hypericum perforatum, povidone iodine, tincture benzoin and tretinoin on wound healing. Food Chem Toxicol. 2022;166:113209. doi:https://doi.org/10.1016/j.fct.2022.113209

140.

Gaid

Füller

Müller-Goymann

. The petroleum ether extract from Hypericum perforatum root cultures exhibits potent antiproliferative activity in human keratinocytes and fibroblasts. Planta Med. 2019;85(7):591-598. doi:https://doi.org/10.1055/a-0806-7735

141.

Füller

Müller-Goymann

. Anti-proliferative and anti-migratory effects of hyperforin in 2D and 3D artificial constructs of human dermal fibroblasts - A new option for hypertrophic scar treatment? Eur J Pharm Biopharm. 2018;126:108-114. doi:https://doi.org/10.1016/j.ejpb.2017.03.003

142.

Tang

Cao

Ding

, et al. Wubeizi ointment suppresses keloid formation through modulation of the mTOR pathway. Biomed Res Int. 2020;2020:3608372. doi:https://doi.org/10.1155/2020/3608372

143.

Tang

Ding

Zhai

Jing

Guan

. MicroRNA-21 may be involved in the therapeutic effects of Galla chinensis ointment on keloid. J Int Med Res. 2020;48(3):300060520909602. doi:https://doi.org/10.1177/0300060520909602

144.

Zhai

Ding

Tang

Chen

Zhang

. Effect of wubeizi ointment aqueous solution on the expression of type I and III procollagen genes in keloid fibroblasts. Exp Ther Med. 2017;13(2):503-506. doi:https://doi.org/10.3892/etm.2016.4017

145.

Ding

Tang

Zhai

Chen

Zhang

. The effects of Wubeizi ointment on the proliferation of keloid-derived fibroblasts. Cell Biochem Biophys. 2015;71(1):431-435. doi:https://doi.org/10.1007/s12013-014-0219-7

146.

Bailly

. Efficacy and safety of the traditional herbal medication chai-ling-tang (in China), Siryung-tang (in Republic of Korea) or Sairei-to (in Japan). J Ethnopharmacol. 2024;319:117127. doi:https://doi.org/10.1016/j.jep.2023.117127

147.

Morimoto

Kakudo

Mitsui

, et al. The effectiveness of saireito, a traditional Japanese herbal medicine, in reducing postoperative edema after acquired ptosis surgery: a prospective controlled trial. Evid Based Complement Alternat Med. 2018;2018:4742305. doi:https://doi.org/10.1155/2018/4742305

148.

Kato

Hayashi

Kitahara

, et al. Saireito (TJ-114), a Japanese traditional herbal medicine, reduces 5-fluorouracil-induced intestinal mucositis in mice by inhibiting cytokine-mediated apoptosis in intestinal crypt cells. PLoS One. 2015;10(1):e0116213. doi:https://doi.org/10.1371/journal.pone.0116213

149.

Soen

Tanabe

Fujita

, et al. The inhibitory effect of Sairei-to on hypertrophic scar formation through TGF-βsignaling. Scar Manag. 2015;9:1-7.

150.

Chuangsuwanich

Arunakul

Kamnerdnakta

. The efficacy of combined herbal extracts gel in reducing scar development at a split-thickness skin graft donor site. Aesthetic Plast Surg. 2013;37(4):770-777. doi:https://doi.org/10.1007/s00266-013-0140-2

151.

Rachpirom

Pichayakorn

Puttarak

. Preparation, development, and scale-up of standardized pentacyclic triterpenoid-rich extract from Centella asiatica (L.) Urb. and study of its wound healing activity. Heliyon. 2023;9(7):e17807. doi:https://doi.org/10.1016/j.heliyon.2023.e17807

152.

Sanguansajapong

Sakdiset

Puttarak

. Development of Oral Microemulsion Spray Containing Pentacyclic Triterpenes-Rich Centella asiatica (L.) Urb. Extract for Healing Mouth Ulcers. Pharmaceutics. 2022;14(11):2531. doi:https://doi.org/10.3390/pharmaceutics14112531

153.

Garg

Dhar

Sharma

Dutt

. Facts about standardization of herbal medicine: a review. Zhong Xi Yi Jie He Xue Bao. 2012;10(10):1077-1083. doi:https://doi.org/10.3736/jcim20121002

Evidence of Potential Natural Products for the Management of Hypertrophic Scars

Abstract

Keywords

Introduction

Methods

Results

Pathomechanism of Wound Healing and Scarring, Particularly Hypertrophic Scarring

Effects of Natural Product-Based Therapeutics on Hypertrophic Scars

Onion

Vitamin E

Gotu Kola

Green Tea

Resveratrol

Emodin

Curcumin

Others

Discussion

Conclusion

Footnotes

Acknowledgments

Author Contributions

Declaration of Conflicting Interests

Ethical Approval

Funding

ORCID iDs

References